

Joint AAD—NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures



Craig A. Elmets, MD (Co-Chair),^a Neil J. Korman, MD, PhD,^b Elizabeth Farley Prater, MD,^c Emily B. Wong, MD,^d Reena N. Rupani, MD,^e Dario Kivelevitch, MD,^f April W. Armstrong, MD, MPH,^g Cody Connor, MD,^a Kelly M. Cordoro, MD,^h Dawn M. R. Davis, MD,ⁱ Boni E. Elewski, MD,^a Joel M. Gelfand, MD, MSCE,^j Kenneth B. Gordon, MD,^k Alice B. Gottlieb, MD, PhD,^l Daniel H. Kaplan, MD, PhD,^m Arthur Kavanaugh, MD,ⁿ Matthew Kiselica, BA, BS,^o Daniela Kroshinsky, MD, MPH,^p Mark Lebwohl, MD,^c Craig L. Leonardi, MD,^q Jason Lichten, MD,^o Henry W. Lim, MD,^r Nehal N. Mehta, MD,^s Amy S. Paller, MD,^t Sylvia L. Parra, MD,^u Arun L. Pathy, MD,^v Michael Siegel, PhD,^w Benjamin Stoff, MD,^x Bruce Strober, MD, PhD,^{y,z} Jashin J. Wu, MD,^{aa} Vidhya Hariharan, PhD,^{bb} and Alan Menter, MD (Co-Chair)^f

Birmingham, Alabama; Cleveland, Ohio; Oklahoma City, Oklahoma; Joint-Base San Antonio and Dallas, Texas; Sinai, New York, New York; Los Angeles, San Francisco, San Diego, and Irvine, California; Rochester, Minnesota; Philadelphia, Pennsylvania; Milwaukee, Wisconsin; Pittsburgh, Pennsylvania; Portland, Oregon; Boston, Massachusetts; St Louis, Missouri; Detroit, Michigan; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Indianapolis, Indiana; Atlanta, Georgia; Cromwell, Connecticut; and New Haven, Connecticut

Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the United States population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine will be reviewed, emphasizing treatment recommendations and the role of dermatologists in monitoring and educating patients regarding benefits as well as risks that may be associated. This guideline will also address the severity assessment methods of psoriasis in adults. (J Am Acad Dermatol 2021;84:432-70.)

Key words: alternative medicine (AM); clinical guidelines for psoriasis; dermatology; guidelines; psoriasis; severity assessment; skin disease; topical agents.

From the University of Alabama, Birmingham^a; University Hospitals Cleveland Medical Center^b; University of Oklahoma Health Sciences Center, Oklahoma City^c; San Antonio Uniformed Services Health Education Consortium, Joint-Base San Antonio^d; Icahn School of Medicine at Mount Sinai, New York^e; Baylor Scott and White, Dallas^f; University of Southern California, Los Angeles^g; the Department of Dermatology, University of California, San Francisco School of Medicine^h; Mayo Clinic, Rochesterⁱ; University of Pennsylvania Perelman School of Medicine, Philadelphia^j; Medical College of Wisconsin, Milwaukee^k; the Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York^l; University of Pittsburgh^m; University of California, San Diegoⁿ; Patient Advocate, National Psoriasis Foundation, Portland^o; Massachusetts General Hospital, Boston^p; Central Dermatology, St Louis^q; the Department of Dermatology, Henry Ford Hospital, Detroit^r; The National Heart Lung and Blood Institute, National Institutes of Health, Bethesda^s; Northwestern University Feinberg School of Medicine, Chicago^t; Dermatology and Skin Surgery, Sumter^u; Colorado

Permanente Medical Group, Centennial^v; Pediatric Dermatology Research Alliance, Indianapolis^w; Emory University School of Medicine, Atlanta^x; Central Connecticut Dermatology Research, Cromwell, Connecticut^y; Yale University, New Haven^z; the Dermatology Research and Education Foundation, Irvine^{aa}; and the American Academy of Dermatology, Rosemont.^{bb}

Funding sources: None.

Conflicts of interest: Listed in text.

IRB approval status: Not applicable.

Accepted for publication July 23, 2020.

Reprints not available from the authors.

Correspondence to: Vidhya Hariharan, PhD, AAD, 9500 W Bryn Mays Ave, Rosemont, IL 60018. E-mail: vhariharan@aad.org.

Published online July 30, 2020.

0190-9622/\$36.00

© 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.jaad.2020.07.087>

Abbreviations used:

AAD:	American Academy of Dermatology
AM:	alternative medicine
AV:	<i>Aloe vera</i>
BSA:	body surface area
DLQI:	Dermatology Life Quality Index
FDA:	Food and Drug Administration
HM:	herbal medicine
LCD:	liquor carbonis detergens
NB-UVB:	narrow band ultraviolet B
NPF:	National Psoriasis Foundation
PASI:	Psoriasis Area Severity Index
PGA:	Physician's Global Assessment
PSI:	Psoriasis Symptom Inventory
RCT:	randomized controlled trial
UVA:	ultraviolet A
UVB:	ultraviolet B
US:	United States
WG:	workgroup

DISCLAIMER

Adherence to these guidelines will not ensure successful treatment in every situation. Furthermore, these guidelines should not be interpreted as setting a standard of care, nor should they be deemed either inclusive of all proper methods of care, or exclusive of other methods of care reasonably directed toward obtaining the same results. The ultimate judgment regarding the propriety of any specific therapy must be made by the physician and the patient in light of circumstances presented by the individual patient and the known variability and biological behavior of the disease. Furthermore, the treatment dosages used in clinical trials may not be effective in certain cases, and some patients may require shorter intervals between doses and/or higher treatment doses of a particular treatment methodology. This guideline reflects the best available data at the time the guideline was prepared. The results of future studies may require revisions to the recommendations in this guideline to reflect new data.

CONFLICT OF INTEREST STATEMENT

The American Academy of Dermatology (AAD) strives to produce clinical guidelines that reflect the best available evidence supplemented with the judgment of expert clinicians. Significant efforts are taken to minimize the potential for conflicts of interest to influence guideline content. The management of conflict of interest for this guideline complies with the Council of Medical Specialty Societies Code of Interactions with Companies. Funding of guideline production by medical or pharmaceutical entities is prohibited, full disclosure is obtained and evaluated for all guideline contributors throughout the guideline development process, and recusal is used to manage identified relationships. The AAD

Table I. Clinical questions

1. What are the efficacy, effectiveness, and adverse events of the following therapies used as monotherapy and/or combination therapy to treat psoriasis in adults?
 - a. Topical corticosteroids
 - b. Calcineurin inhibitors (Topical tacrolimus and pimecrolimus)
 - c. Vitamin D analogues
 - d. Tazarotene
 - e. Moisturizers
 - f. Salicylic acid
 - g. Anthralin
 - h. Coal tar
 - i. Biologic agent combination
 - j. Nonbiologic combination
 - i. Methotrexate
 - ii. Cyclosporine
 - iii. Acitretin
2. What are the efficacy, effectiveness, and adverse events of the following alternative medicines used for adult psoriasis?
 - a. Traditional Chinese medicine
 - b. Herbal therapies
 - i. *Aloe vera*
 - ii. St John's wort
 - c. Diet/dietary supplements
 - i. Fish oil
 - ii. Vitamin D
 - iii. Curcumin (Turmeric)
 - iv. Zinc
 - v. Gluten-free diet
 - d. Mind/body
 - i. Hypnosis
 - ii. Stress reduction/meditation
3. What is the accuracy, clinical utility, and treatment parameters for using the following severity measures to measure psoriasis severity and response to treatment?
 - a. Body surface area (BSA)
 - b. Psoriasis Area and Severity Index (PASI)
 - c. Physician Global Assessment (PGA)
 - d. $PGA \times BSA$
 - e. Psoriasis Symptom Inventory (PSI)
 - f. Dermatology of Life Quality Index (DLQI)
 - g. Pruritus assessment

conflict of interest policy summary may be viewed at www.aad.org.

The information below represents the authors who disclosed a relationship with industry during guideline development. Authors (listed alphabetically) with relevant conflicts with respect to this

Table II. Classification of topical corticosteroid^{6-8*}

WHO potency group	Classification	Topical corticosteroid
Super-potent Ultrahigh	Class 1	1. Augmented betamethasone dipropionate 0.05% ^{a,b}
		2. Clobetasol propionate 0.05% ^{a,b,c,d,e,f,g,h,i}
		3. Desoximetasone 0.25% ^h
		4. Augmented diflorasone diacetate 0.05% ^a
		5. Fluocinonide 0.1% ^c
		6. Flurandrenolide 4 μg/cm ^{2j}
		7. Halobetasol propionate 0.05% ^{a,c}
High	Class 2	1. Amcinonide 0.1% ^a
		2. Betamethasone dipropionate 0.05% ^a
		3. Augmented betamethasone dipropionate 0.05% ^{c,d}
		4. Desoximetasone 0.25% ^{a,c}
		5. Desoximetasone 0.05% ^b
		6. Augmented diflorasone diacetate 0.05% ^c
		7. Diflorasone diacetate 0.05% ^a
		8. Fluocinonide 0.05% ^{a,b,c,f}
		9. Halcinonide 0.1% ^{a,c}
		10. Mometasone furoate 0.1% ^a
		11. Triamcinolone acetonide 0.5% ^a
	Class 3	1. Amcinonide 0.1% ^{c,d}
		2. Betamethasone dipropionate 0.05% ^{c,k}
		3. Betamethasone valerate 0.1% ^a
		4. Betamethasone valerate 0.12% ^l
		5. Diflorasone diacetate 0.05% ^c
		6. Fluticasone propionate 0.005% ^a
		7. Triamcinolone acetonide 0.1% ^a
		8. Triamcinolone acetonide 0.5% ^c
Moderate (medium)	Class 4	1. Betamethasone valerate 0.12% ^l
		2. Desoximetasone 0.05% ^c
		3. Fluocinolone acetonide 0.025% ^a
		4. Flurandrenolide 0.05% ^a
		5. Hydrocortisone valerate 0.2% ^a
		6. Mometasone furoate 0.1% ^{c,d}
		7. Triamcinolone acetonide 0.1% ^{c,m}
		8. Triamcinolone acetonide 0.2% ^h
	Class 5	1. Betamethasone dipropionate 0.05% ^k
		2. Betamethasone valerate 0.1% ^{c,d}
		3. Clocortolone pivalate 0.1% ^c
		4. Fluocinolone acetonide 0.025% ^c
		5. Fluocinolone acetonide 0.01% ^{n,o}
		6. Fluticasone propionate 0.05% ^{c,d}
		7. Flurandrenolide 0.05% ^{c,d}
		8. Hydrocortisone butyrate 0.1% ^{a,c,d,f}
		9. Hydrocortisone probutate 0.1% ^c
		10. Hydrocortisone valerate 0.2% ^c
		11. Prednicarbate 0.1% ^{a,c}
		12. Triamcinolone acetonide 0.025% ^a
		13. Triamcinolone acetonide 0.01% ^d

Continued

Table II. Cont'd

WHO potency group	Classification	Topical corticosteroid
Low	Class 6	1. Alclometasone dipropionate 0.05% ^{a,c} 2. Betamethasone valerate 0.05% ^d 3. Desonide 0.05% ^{a,b,c,d,e} 4. Fluocinolone acetonide 0.01% ^{c,f} 5. Triamcinolone acetonide 0.025% ^{c,d}
	Class 7	1. Dexamethasone sodium phosphate 0.1% ^c 2. Hydrocortisone 0.5%-2.5% ^{a,b,c,d,f} 3. Methylprednisolone acetate 0.25% ^c

WHO, World Health Organization.

*Reprinted from *Dermatology*: 2-Volume Set, 4th Edition, Jean Bolognia, Julie Schafer, and Lorenzo Cerroni, Glucocorticosteroids, Page No. 2190, Copyright 2018, with permission from Elsevier.

^aOintment.

^bGel.

^cCream.

^dLotion.

^eFoam.

^fSolution.

^gScalp solution application, in some classifications class 2.

^hSpray.

ⁱShampoo 0.05%.

^jTape.

^kLotion, depending upon classification, class 3 or 5.

^lFoam, depending upon classification, class 3 or 4.

^mKenalog ointment (manufactured by APOTHECON, a Bristol-Myers Squibb Company; Princeton, NJ).

ⁿOil.

^oShampoo.

guideline are noted with an asterisk (*). In accordance with the AAD policy, fewer than 51% of workgroup members had any relevant conflicts of interest.

Participation in one or more of the below-listed activities constitutes a relevant conflict:

- service as a member of a speaker bureau, consultant, advisory board, for pharmaceutical companies on the psoriasis disease state or psoriasis drugs in development or United States (US) Food and Drug Administration (FDA) approved;
- sponsored research funding or investigator-initiated studies with partial/full funding from pharmaceutical companies on the psoriasis disease state or psoriasis drugs in development or FDA approved.

Draft guideline recommendations were developed through a collaborative approach between conflicted and nonconflicted section leaders. Initial recommendations were presented to the full workgroup for finalization.

SCOPE

This guideline will cover the use of topical agents and alternative medicine (AM) in the treatment of psoriasis in adults as well as the assessment of disease

severity; psoriasis in the pediatric population will be covered in a separate guideline section, "Joint American Academy of Dermatology-National Psoriasis Foundation (NPF) guidelines of care for the management and treatment of psoriasis in pediatric patients."¹

METHOD

For a full description of the methodology used herein, please refer to the [Appendix](#) section.

DEFINITION OF REVIEW

See the [Appendix](#) for full definition statement.

INTRODUCTION

Psoriasis is a common inflammatory disease, affecting approximately 3.2% of the population.² While skin involvement is the most prominent manifestation of this disease, recognition of psoriasis as a chronic, multisystem inflammatory disorder is imperative to optimize management and reduce comorbidities.

Topical medications are the most common agents used to treat patients with mild to moderate psoriasis. They are frequently used as adjunctive therapies for patients on phototherapy, systemic, or biologic therapy. Alternative medicine (AM) is not typically part of conventional medical care. It may have

origins outside of usual Western practice and may be desired by and benefit a subset of patients.^{3,4}

This section will review the assessment of psoriasis severity and the management and treatment of psoriasis with topical therapy and AM modalities in adult psoriasis patients (Table I).

I. TOPICAL AGENTS

Topical corticosteroids

Efficacy. Topical corticosteroids, which provide high efficacy and good safety, play a key role in the treatment of psoriasis, especially for localized disease. Topical corticosteroids have anti-inflammatory, antiproliferative, immunosuppressive, and vasoconstrictive effects. These effects are exerted via intracellular corticosteroid receptors, which regulate gene transcription, including several that code for proinflammatory mediators. Topical corticosteroids are classified into 7 categories based on their skin vasoconstrictive activity, ranging in strength from ultra-high (class 1) to low (class 6 and 7; Table II).⁵⁻⁸

Choosing a corticosteroid with appropriate potency plus the appropriate vehicle should be based on the disease severity, disease location, patient preference, and the age of the patient. Lower potency corticosteroids should be used on the face, intertriginous areas, and areas that are susceptible to steroid atrophy (eg, forearms) and other adverse effects. In adults, corticosteroids in classes 2 through 5 (moderate to high potency; Table II) are generally recommended as initial therapy. Areas with thick, chronic plaques often require treatment with class 1 (ultrahigh-potency) corticosteroids. In numerous randomized controlled trials (RCTs), different potency topical corticosteroids were effective and safe at 2 to 4 weeks in the treatment of mild to severe plaque psoriasis.⁹⁻¹¹ Evidence on the efficacy of topical corticosteroids from RCTs varies due to the differences in study designs, patient populations, and end points, making it difficult to do an accurate statistical comparison of the majority of published studies.

For ultrahigh-potency (class 1) corticosteroids, the efficacy rates in several RCTs vary from 58% to 92%.^{9,10,12,13} In a double-blind, vehicle-controlled trial of 204 patients with moderate to severe psoriasis, after 2 weeks of treatment, the halobetasol propionate ointment (class 1) group improved the Physician's Global Assessment (PGA) scores by 92% compared with 39% in vehicle-treated patients ($P < .0003$).⁹ An RCT of 279 patients with mild to moderate psoriasis found that after 2 weeks of treatment with clobetasol foam (class 1), 68% of patients achieved a Physician's Static Global Assessment (PSGA) score of 0 or 1 compared with

21% of patients treated with vehicle ($P < .0001$).¹⁰ Another double-blind RCT of 81 patients used the Investigator Global Assessment scale to assess patients with mild to moderate psoriasis and demonstrated that after 2 weeks of treatment with clobetasol foam (class 1), 58% of patients achieved moderate or marked improvement, or almost or completely clear psoriasis compared with 15% in vehicle-treated patients ($P < .0005$).¹¹

For high-potency (class 2 and 3) corticosteroids, the efficacy rates in several RCTs vary from 68% to 74%. In a double blind-RCT of 35 patients with psoriasis treated with 0.25% desoximetasone cream (class 2) for 3 weeks, 68% of the desoximetasone group compared with 23% of the vehicle group achieved improvement in their mean overall evaluation scores ($P < .001$).¹⁴ Two RCTs with fluticasone propionate 0.005%, a class 3 corticosteroid, showed 68% to 69% of patients with moderate to severe psoriasis in the treatment group achieved, good, excellent, or clear skin after 4 weeks compared with 29% to 30% in the vehicle group ($P = .00001$).¹⁵

For moderate-potency (class 4 and 5) corticosteroids, the efficacy rates in several RCTs vary from 70% to 83%.^{16,17} An RCT of 40 patients with nonscalp psoriasis revealed that 70% of patients treated with betamethasone valerate foam 0.12% (class 4) achieved greater than 50% improvement compared with 24% of patients in the placebo group after 12 weeks of treatment ($P < .001$).¹⁷ In an RCT of patients with moderate to severe scalp psoriasis, the group treated with fluocinolone acetonide 0.01% oil (class 5 corticosteroid) had a higher proportion of patients achieving good or better improvement from baseline compared with the vehicle-treated group after 3 weeks of treatment (83% vs 36%; $P < .001$).¹⁶ Additionally, an RCT showed that fluticasone propionate 0.05% cream (class 5) was superior to hydrocortisone butyrate 0.1% cream (class 7) in achieving clearance, excellent, or good treatment response after 3 weeks of treatment (79% vs 68%; $P < .05$).¹⁸

Owing to the inconsistent criteria in RCT design, comparisons between different corticosteroids and classes are complex. Nevertheless, a systematic review of topical corticosteroids for the treatment of psoriasis revealed that potent and super-potent topical corticosteroids were more efficacious than mild or moderately potent corticosteroids.¹⁹

Treatment of psoriasis in intertriginous areas, such as the groin, or hair-bearing skin, such as the scalp, can be challenging due to the difficulty of applying a topical product to these areas based on the vehicle selection. Therefore, appropriate selection of the vehicle depending on hair density and individual hairstyles and preferences is essential for the efficacy

Table III. Recommendations and strength of recommendation for topical corticosteroids

Reference number	Recommendations	Strength of recommendation
1.1	The use of class 1, class 2, and class 3-5 topical corticosteroids for up to 4 weeks is recommended for the treatment of plaque psoriasis not involving intertriginous areas	A
1.2	The use of class 1-7 topical corticosteroids for a minimum of up to 4 weeks is recommended as initial and maintenance treatment of scalp psoriasis	A
1.3	The use of topical corticosteroids for >12 weeks can be considered if done under the careful supervision of a physician	C

of the treatment. Several RCTs and systematic reviews of scalp psoriasis treatment demonstrate the safety and efficacy of various potency topical corticosteroids used for 3 to 12 weeks.^{16,17,20} The duration of the therapy depends on factors such as the strength of topical corticosteroids, the severity of the disease, anatomic location, and age of the patient. Similarly, a steroid-sparing agent can be considered to avoid adverse effects.

Additionally, intralesional corticosteroids can be used for localized nonresponding or very thick lesions on glabrous skin, scalp, nails, palms, and soles. Several studies and reports have shown that intralesional corticosteroids can be effective for the treatment of psoriasis.²¹⁻²³ Triamcinolone acetonide in a dose up to 20 mg/mL can be used every 3 to 4 weeks.²⁴ The injection volume varies pending lesion size and the area affected.

Risks/harms and benefits. The most common local skin adverse effects of topical corticosteroid use include skin atrophy, striae, folliculitis, telangiectasia, and purpura.²⁵ Face and intertriginous areas, as well as chronically treated areas, especially forearms, are at greatest risk to develop these adverse effects. Topical corticosteroids may exacerbate acne, rosacea, perioral dermatitis, and tinea infections and may occasionally cause contact dermatitis. Rebound (ie, when the disease recurs and is more severe than before treatment) can occur from abrupt withdrawal of topical corticosteroids, although the frequency

Table IV. Level of evidence for topical corticosteroids

Recommendation	Reference number	Level of evidence	Studies
Topical corticosteroid for plaque psoriasis not involving intertriginous areas	1.1	I	9-11,13,15,45-47
Topical corticosteroid for scalp psoriasis	1.2	I	16,17,20
Long-term use of topical corticosteroid	1.3	III	Expert opinion

and severity of this phenomenon are unknown. The daily use of ultrahigh- and high-potency (class 1-3) corticosteroids for up to 4 weeks is generally safe with minimal risk of skin atrophy.²⁶

Risk of hypothalamic-pituitary-adrenal axis suppression from the use of topical corticosteroids for extensive plaque or scalp psoriasis has been reported to be low.²⁶ In a systematic review of 13 randomized studies, studies performed for up to 4 weeks found the percentage of patients with a reduction in the morning cortisol level was 0% with halobetasol or fluocinonide, 0% to 48% with clobetasol propionate, and 0% to 18% with betamethasone dipropionate. Nevertheless, results of adrenocorticotropic hormone stimulation tests, the gold standard for assessing hypothalamic-pituitary-adrenal axis suppression, were always within normal reference ranges, even when assessed after 6 to 12 months of topical corticosteroid use.²⁶ Rare systemic adverse effects include Cushing syndrome and osteonecrosis of the femoral head.^{27,28} Topical products that contain corticosteroid should not be used for more than 12 weeks for nail disease, because there are isolated reports of bone atrophy with persistent use.^{29,30} Increased intraocular pressure, glaucoma, and cataracts have been rarely reported with the use of topical corticosteroids around the eye.^{31,32} In rare cases, type 2 diabetes has been reported with topical corticosteroid use.³³

Despite the safety data,²⁶ caution is advised, because the greatest risk for systemic adverse effects occurs when ultrahigh- or high-potency corticosteroids are used over a large surface (>20% body surface area [BSA]) or under occlusion for a prolonged period (>4 weeks). Clinicians should consider limiting the use of class 1 corticosteroids to no more than twice daily for up to 4 weeks, when possible.³⁴ In the event of a flare, repeated courses of a class 1 corticosteroid can be administered. Longer durations of class 1 corticosteroid therapy for psoriasis of the palms and soles are acceptable with close

attention to the development of potential adverse effects. Gradual reduction in the frequency of use after clinical improvement is recommended, but the exact details of this tapering are not well established. Topical corticosteroids can be tapered off by reducing use to every other day, then eventually 2 times a week, and finally discontinuation if psoriasis is well controlled and stable during the whole process. To minimize the adverse effects of topical corticosteroids, transitioning to lower-potency agents after improvement, using intermittent therapy, and combining treatment with noncorticosteroidal agents can also be considered.

Topical corticosteroids are safe during pregnancy when low cumulative doses (<60 g/wk) are used (expert consensus). In rare cases, low fetal birth weight has been reported with prolonged potent topical corticosteroid use during pregnancy.³⁵ Further, there is a single case report of a nursing mother who applied a potent topical corticosteroid on the nipple and the infant developed hypertension.³⁶ Therefore, the use of a super potent corticosteroid in the nipple and the areola area should be avoided in nursing mothers.^{37,38}

General comments. Because psoriasis generally recurs after discontinuation of topical corticosteroid treatment, it is important to consider using steroid-sparing agents that have been developed to supplement and reduce over-reliance on topical corticosteroids as monotherapy, decreasing the risk of corticosteroid adverse effects.²⁶ Agents such as vitamin D analogues, topical retinoids, and calcineurin inhibitors can be used as a maintenance treatment. For example, a therapeutic regimen for mild psoriasis flares could include 2 to 4 weeks of treatment with a topical corticosteroid twice daily, followed by maintenance with a steroid-sparing agent twice daily on weekdays, and a corticosteroid agent twice daily on weekends.³⁹ Treatment as discussed above can be reinstated when a new flare occurs.

“Proactive treatment” is another strategy for optimal topical management of psoriasis during maintenance that is helpful. Proactive treatment refers to topical treatment of areas that are clinically quiescent but are usually involved in recurrence. It typically involves twice-weekly treatment of these clinically quiescent areas to reduce the frequency of flares.^{40,41} Proactive treatment can be implemented with any of the topical agents discussed in these guidelines.

Tachyphylaxis is defined as the loss of effectiveness of topical corticosteroids with continued use. Tachyphylaxis may compromise the effectiveness in certain patients when used for an extended period >12 weeks. Whether tachyphylaxis represents a true loss of effectiveness of the medication or a loss of

adherence on the part of patients is controversial. Current suggestions are based on extrapolation from animal studies, and further research into this subject is needed. Recommendations on the use of topical corticosteroids and its supporting evidence can be found in [Tables III](#) and [IV](#).^{9-11,13,15-17,20,39,42-47}

Calcineurin inhibitors

Efficacy. Topical calcineurin inhibitors bind to calcineurin, blocking its phosphorylation and thus, inhibiting T-cell activation and the synthesis of several proinflammatory cytokines that play a critical role in the pathogenesis of psoriasis. Although not FDA approved for psoriasis, the topical calcineurin inhibitors tacrolimus and pimecrolimus are often used in the treatment of psoriasis. They are especially helpful on thinner skin, such as facial and intertriginous areas, and are used as steroid-sparing agents for prolonged use (>4 weeks). Most of the data regarding these medications are derived from their extensive use in atopic dermatitis.

Several RCTs support the use of pimecrolimus for the treatment of intertriginous psoriasis.^{48,49} In a double-blind RCT of 57 patients with intertriginous psoriasis, after 8 weeks of twice-daily treatment, 71% of the patients in the pimecrolimus 0.1% cream group were clear or almost clear compared with 21% of patients in the placebo group (treatment difference in target area score was -1.810; 95% confidence interval -2.801 to -0.819).⁴⁹ Several RCTs also support the use of tacrolimus for the treatment of facial and intertriginous psoriasis.⁵⁰ In a double-blind RCT of 167 patients with facial and intertriginous psoriasis, after 8 weeks of therapy, 65% of patients in the tacrolimus 0.1% ointment group were clear or almost clear compared with 31% of patients in the placebo group.⁵¹ Recommendations on the use of topical calcineurin inhibitors and its supporting evidence can be found in [Tables V](#) and [VI](#).^{48-52,61}

The off-label combination of tacrolimus and 6% salicylic acid for 12 weeks may be used for the treatment of plaque psoriasis.⁵²

Risks/harms and benefits. Studies from atopic dermatitis have reported that tacrolimus and pimecrolimus can both cause burning and pruritus.⁵³⁻⁵⁶ These adverse events generally improve with continued use and can be mitigated by avoiding application to moist skin.^{53,54}

In 2005, the FDA issued a boxed warning citing concerns that long-term, intermittent use of pimecrolimus or tacrolimus could lead to an increased incidence of lymphoma. This warning was due to a theoretical increased risk of lymphoma with the systemic use of these agents based on animal data, isolated case reports, and the mechanism of action of

Table V. Recommendations and strength of recommendation for topical pimecrolimus and tacrolimus

Reference number	Recommendations	Strength of recommendation
2.1	The off-label use of 0.1% tacrolimus for psoriasis involving the face as well as inverse psoriasis for up to 8 weeks can be considered	B
2.2	The off-label use of pimecrolimus for inverse psoriasis for 4-8 weeks is recommended	B
2.3	Long-term use of tacrolimus or pimecrolimus can be considered for inverse psoriasis treatment as off-label use	C
2.4	The off-label combination of tacrolimus and 6% salicylic acid for 12 weeks may be used for the treatment of plaque psoriasis	B

these drugs. Although both agents carry a boxed warning related to the potential risk for malignancy (eg, skin and lymphoma), there is no evidence showing an increased risk of malignancy with the topical use of either agent.^{53,54,57-59} A common adverse effect of calcineurin inhibitors includes flushing with the ingestion of alcohol.^{53,54}

The effects in humans of tacrolimus and pimecrolimus on the fetus are unknown. If they are used during pregnancy, they should, therefore, be used cautiously. Breastfeeding mothers should avoid use on the nipple but can use them on other areas, because maternal systemic absorption is minimal.^{53,54,60} Additionally, no signs of reduced fertility were found in men and women using tacrolimus.⁵⁴ Similarly, in animal studies, no signs of reduced fertility were associated with pimecrolimus.⁵³

Contraindication. There are no specific contraindications, but much of the data (except that given above for facial and intertriginous psoriasis) regarding these medications are derived from their extensive use in atopic dermatitis.

Vitamin D analogues

Efficacy. Vitamin D analogs exert their effect in psoriasis by binding to vitamin D receptors, which inhibit keratinocyte proliferation and enhance keratinocyte differentiation. Calcipotriene (also known

Table VI. Level of evidence for topical pimecrolimus and tacrolimus

Recommendation	Reference number	Level of evidence	Studies
Use of 0.1% tacrolimus for psoriasis involving the face/inverse psoriasis	2.1	I	50,51
Use of pimecrolimus for inverse psoriasis	2.2	I	48,49
Long-term use of tacrolimus or pimecrolimus for inverse psoriasis	2.3	III	61
Combination of tacrolimus and 6% salicylic acid for plaque psoriasis	2.4	II	52

as calcipotriol) and calcitriol are the 2 commonly used synthetic vitamin D analogues. Calcipotriene is available in several formulations in the US, but topical calcitriol is only available as an ointment. Tacalcitol and maxacalcitol are vitamin D analogues available worldwide, but not currently in the US. Additionally, calcipotriene and tacalcitol are available in combination with topical corticosteroids.

Several studies have shown that 4 to 8 weeks' treatment of calcipotriene, calcitriol, tacalcitol, and maxacalcitol is safe and efficacious for treating mild to moderate psoriasis.⁶²⁻⁶⁴ Two double-blind RCT compared calcipotriene foam to the vehicle for the treatment of plaque psoriasis. In the first study, 14% of patients in the calcipotriene foam group vs 7% in the vehicle foam group achieved treatment success after 8 weeks ($P = .058$). In the second study, treatment success and the primary end point, defined as achieving an Investigator's Static Global Assessment score of 0 (clear) or 1 (almost clear), was achieved by more participants in the calcipotriene foam group (27% vs 16%; $P = .016$).⁶⁵

A 6-week double-blind RCT in 258 patients with plaque psoriasis showed that calcitriol ointment had comparable efficacy, defined as a mean reduction of Psoriasis Area and Severity Index (PASI), to betamethasone dipropionate 0.05% ointment (10.6% and 9.67%, respectively).¹² During the follow-up after treatment, 48% of patients who applied calcitriol and 25% of patients who applied betamethasone dipropionate remained in remission ($P < .01$). Treatment with calcipotriene foam for 8 weeks and calcipotriene plus betamethasone dipropionate gel for 4 to 12 weeks compared with placebo was safe and effective for the treatment of mild to moderate scalp psoriasis.^{66,67}

An 8-week double-blind RCT with 363 patients with psoriasis used the Investigator's Static Global Assessment to measure its primary outcome. After 8 weeks, calcipotriene foam (40.9%) was more effective in achieving an Investigator's Static Global Assessment score of 0 (clear) or 1 (almost clear) compared with vehicle (24.2%) for the treatment of scalp psoriasis ($P < .001$).⁶⁸ The efficacy of vitamin D analogues was noted at 8 weeks but not at 4 weeks. This can be considered and addressed with patients when planning appropriate topical treatment.

The use of calcipotriene or tacalcitol ointment combined with hydrocortisone is efficacious for the treatment of facial psoriasis.⁶⁹ Topical calcipotriene has displayed greater efficacy than 6% coal tar or salicylic acid but less efficacy than liquor carbonis detergens (LCD) 15% solution.^{70,71} An 8-week double-blind RCT ($n = 409$) with 4 treatment arms compared calcipotriene 25 $\mu\text{g/g}$, calcipotriene 25 $\mu\text{g/g}$ plus hydrocortisone 10 mg/g, calcipotriene 50 $\mu\text{g/g}$, and calcipotriene 50 $\mu\text{g/g}$ plus hydrocortisone 10 mg/g.⁷² All treatments were equally effective on the body, but the treatments containing hydrocortisone were more effective on the face, as determined by a score of 0 or 1 in the Investigator Global Assessment of the face (odds ratio, 2.01; 95% confidence interval, 1.33-3.05, $P = .001$).⁷²

The use of combination treatments with vitamin D analogues and potent topical corticosteroids from 3 to 52 weeks is more effective than either agent alone for the treatment of psoriasis.⁷³⁻⁸⁴ A systematic review of RCTs concluded that when given for 3 to 8 weeks, ultrapotent or potent corticosteroid treatments outperform calcipotriene. The outcome measures assessed in the review included Investigator Global Assessment, PASI, and PGA which were translated to a 6-point improvement scale. Nevertheless, calcipotriene combined with potent betamethasone dipropionate was slightly more efficacious than betamethasone as a monotherapy.⁸⁵ In a 52-week study with 828 patients, 69% to 74% of patients in the group treated with calcipotriene 0.005% plus betamethasone 0.064% once or twice daily achieved clear or almost clear status compared with 27% of the patients treated with vehicle control ($P < .001$). No serious adverse events, including striae or hypothalamic-pituitary-adrenal axis suppression, were observed over the 52-week treatment period with calcipotriene 0.005% and betamethasone 0.064%.⁸¹

There is evidence supporting the application of vitamin D analogues twice daily on weekdays in conjunction with high-potency topical corticosteroids twice daily on weekends.³⁹ An open-label

study in 70 patients showed treatment with calcipotriene ointment on weekdays and clobetasol spray on weekends applied twice daily for 4 weeks is an effective treatment regimen for moderate plaque psoriasis.³⁹ Additionally, the application of morning high-potency topical corticosteroids and evening topical vitamin D analogues is an effective combination regimen for the treatment of psoriasis.⁸⁶ In an open-label study, 68 patients applied an morning/evening regimen of clobetasol propionate spray 0.05% and calcipotriene ointment 3 $\mu\text{g/g}$. At 4 weeks, 85.5% of patients were clear, almost clear, or had mild involvement.⁸⁶

Risks/harms and benefits. Vitamin D analogues are considered safe for the treatment of plaque psoriasis. No clinical or experimental evidence has been found relating to tachyphylaxis with topical vitamin D analogue use in psoriasis. Other local adverse effects can affect up to 35% of patients and include burning, pruritus, edema, peeling, dryness, and erythema. They may occur both on lesional and perilesional skin. With continued treatment, these adverse effects usually subside or disappear. Systemic adverse effects due to topical vitamin D analogues include hypercalcemia and parathyroid hormone suppression. These effects are quite rare unless more than 30% BSA is treated, the recommended dose is exceeded, or the patient has an underlying renal disease or impaired calcium metabolism. When using calcipotriene, applications of more than 100 g/wk should be avoided to minimize this risk.⁸⁷ Calcipotriene over 52 weeks was well tolerated in an open-label study of 132 patients. Mild hypercalcemia occurred in 3.1% of patients that did not correlate with the length of treatment or pretreatment BSA.²² Vitamin D analogues may be used during pregnancy and lactation if the benefit outweighs the risk. The use of vitamin D combination products containing corticosteroids on more than 15% BSA once daily rarely induces adrenal suppression.⁸⁸

General comments. Ultraviolet A (UVA) radiation can decrease the concentration of calcipotriene on the skin. Conversely, thick layers of calcipotriene can block ultraviolet B (UVB), thereby increasing the minimal erythema dose.⁸⁹ Vitamin D analogues can be used in conjunction with phototherapy but should be applied after the phototherapy treatment to avoid inactivation by UVA and blocking UVB radiation.⁹⁰ Combining separate vitamin D and corticosteroid preparations into specific easy-to-follow regimens can be used to reduce both the adverse effects of topical corticosteroids and the cost for some patients, as discussed above in the topical corticosteroid section. Additionally, the

Table VII. Recommendations and strength of recommendation for vitamin D analogues

Reference number	Recommendations	Strength of recommendation
3.1	The long-term use of topical vitamin D analogues (up to 52 weeks), including calcipotriene/calcipotriene, calcitriol, tacalcitol, and maxacalcitol, is recommended for the treatment of mild to moderate psoriasis	A
3.2	Use of calcipotriene foam and calcipotriene plus betamethasone dipropionate gel is recommended for 4-12 weeks for the treatment of mild to moderate scalp psoriasis	A
3.3	Topical tacalcitol ointment or calcipotriene combined with hydrocortisone for 8 weeks can be used for the treatment of facial psoriasis	B
3.4	Use of combination treatments with vitamin D analogues and potent class II and class III topical corticosteroids up to 52 weeks is recommended for the treatment of psoriasis	A
3.5	Use of combination products with calcipotriol and corticosteroids is recommended for the treatment of psoriasis	A
3.6	The application of vitamin D analogues twice daily on weekdays in conjunction with high-potency topical corticosteroids twice daily on weekends can be considered for maintenance treatment for psoriasis	B
3.7	The application of morning high-potency topical corticosteroids and evening topical vitamin D analogues is an effective treatment regimen that can be considered for the treatment of psoriasis	B

simultaneous use of salicylic acid with calcipotriene should be avoided because the acid pH of salicylic acid will inactivate calcipotriene and reduce its effectiveness.

Topical vitamin D analogues combined with betamethasone dipropionate can be used for the treatment of nail psoriasis to reduce nail thickness, hyperkeratosis, onycholysis, and pain.³⁰ These agents have limitations in treating severe nail disease due to poor penetration, particularly of the nail matrix.⁹¹ Topical maxacalcitol (not available in the US) ointment can be considered as an initial treatment for palmoplantar psoriasis, including palmoplantar pustulosis.^{92,93}

Other combination treatments. Calcipotriene ointment combined with topical tacrolimus is more efficacious than tacrolimus alone.⁹⁴ Combination products with calcipotriene and topical nicotinamide are effective for the treatment of mild to moderate psoriasis. Recommendations on the use of vitamin D analogues and its supporting evidence can be found in [Tables VII and VIII](#).*

Tazarotene

Efficacy. Tazarotene is a topical retinoid available for the treatment of psoriasis since 1997. It exerts its therapeutic effects by acting on keratinocyte differentiation and proliferation and by downregulating the expression of proinflammatory genes. The use of topical tazarotene for 8 to 12 weeks is recommended for the treatment of mild to moderate

psoriasis, with several studies demonstrating its efficacy.¹⁰²⁻¹⁰⁵ In 2 RCT of 1303 patients with plaque psoriasis, 40% and 51% of patients treated with tazarotene (0.1% cream and 0.05% cream, respectively) compared with 25% of patients treated with the vehicle once daily for 12 weeks achieved treatment success, defined as overall lesional assessment of none, minimal, or mild psoriasis activity (*P* for trend = .04).¹⁰⁶ A 12-week RCT showed that the efficacy of tazarotene 0.1% gel for the treatment of plaque psoriasis was comparable to fluocinonide cream. The efficacy was assessed by measuring plaque elevation, scaling, and erythema (grading each from 0 to 4) of target lesions at baseline and at each follow-up visit. Treatment success was defined as 50% to 74% improvement.¹⁰³

An RCT showed that the combination of tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment was more effective than tazarotene gel alone in maintaining clearance after 20 weeks.¹⁰⁷ Tazarotene can also be combined with phototherapy. An RCT showed tazarotene plus narrowband UVB (NB-UVB) therapy improved the efficacy of phototherapy and decreased the amount of UV radiation needed to achieve 50% or better improvement from baseline using the 6-point global improvement scale.¹⁰⁸

A double-blind RCT compared the efficacy of tazarotene 0.1% cream with clobetasol 0.05% cream, both under occlusion, for 12 weeks for nail psoriasis. The efficacy was assessed using the Nail Psoriasis Severity Index. At 12 weeks, both groups showed significant improvement in the Nail Psoriasis Severity Index with respect to onycholysis, pitting,

*References 12,20,22,39,65-69,72-80,82-84,86,95-101.

Table VIII. Level of evidence for vitamin D analogues

Recommendation	Reference number	Level of evidence	Studies
Topical vitamin D analogues therapy	3.1	I-II	12,20,22,65,96
Treatment with calcipotriene foam and calcipotriene plus betamethasone dipropionate gel for scalp psoriasis	3.2	I	66-68,97
Topical tacalcitol ointment or calcipotriene combined with hydrocortisone for facial psoriasis	3.3	I-II	69,72
Combination treatments with vitamin D analogues and potent topical corticosteroids for psoriasis	3.4	I-II	73-80,85,98
Combination products with calcipotriene and corticosteroids for psoriasis	3.5	I-III	82-84,99-101
Application of vitamin D analogues twice daily on weekdays in conjunction with high-potency topical corticosteroids twice daily on weekends	3.6	II	39
Morning high-potency topical corticosteroids and evening topical vitamin D analogues	3.7	II	86

hyperkeratosis, and oil spots (salmon patches). Additionally, the difference in efficacy between both groups was not statistically significant.¹⁰⁹ A smaller double-blind, placebo-controlled clinical trial with 31 patients assessed the efficacy of tazarotene for the treatment of nail psoriasis. After 24 weeks of treatment, tazarotene 0.1% gel showed a significantly greater reduction of onycholysis (in occluded and nonoccluded nails) and pitting (in occluded nails) compared with placebo ($P \leq .05$).¹¹⁰

Risks/harms and benefits. Potential adverse effects include erythema, burning, and pruritus and are more prominent at higher concentrations.¹¹¹ Avoid the application of the formulation to uninvolved skin to minimize irritation. These adverse effects can be reduced by using a cream formulation or lower concentration formulation, combining tazarotene with moisturizers, applying it on alternate days, or short-contact (30 to 60 minutes) treatment, and combining it with topical corticosteroids.¹¹² The combination of tazarotene with halobetasol is beneficial because it reduces the irritation caused by tazarotene. Additionally, the combination reduces the amount of topical corticosteroids needed, thereby limiting atrophy produced by halobetasol.¹¹³

Tazarotene should be avoided in pregnant women. In women of childbearing age, a negative pregnancy test should be obtained 2 weeks before starting tazarotene, according to the package insert.¹¹² Women of childbearing age should be counseled to discontinue tazarotene if they become pregnant. No human data are available on excretion in human milk. No signs of fertility reduction based on animal studies have been reported.¹¹²

Contraindication. Tazarotene should not be used in pregnant women.

Topical corticosteroids and tazarotene. The use of a medium- or high-potency topical corticosteroid in combination with tazarotene for 8 to 16 weeks is recommended for the treatment of mild to moderate psoriasis.¹¹⁴ There may be a synergistic effect when topical corticosteroids are used along with tazarotene, and this combination also increases the duration of treatment effect as well as the time of remission.^{107,115} A multicenter RCT of 300 patients with stable plaque psoriasis with 20% BSA or less involved treated with tazarotene 0.1% gel once daily, alone or combined with low-, medium-, or high-potency topical corticosteroids, demonstrated the combination of tazarotene with medium- or high-potency topical corticosteroid increased efficacy while reducing local adverse events.¹¹⁶ For details related to the treatment of psoriasis with tazarotene monotherapy as well as potential risk/harm, refer to the respective section below. Tazarotene is contraindicated during pregnancy and should be discontinued if pregnancy is recognized.¹¹²

General comments. Topical tazarotene can be particularly helpful for palmar-plantar psoriasis and nail psoriasis. Topical tazarotene studies have reported similar efficacy to fluocinonide cream, crude coal tar 5% ointment, and calcipotriene 0.005% ointment.¹⁰³⁻¹⁰⁵ Topical corticosteroids can be added to topical tazarotene to increase efficacy. Recommendations on the use of topical tazarotene and its supporting evidence can be found in [Tables IX and X](#).^{102-108,114-118}

Moisturizers

Efficacy. Nonmedicated moisturizers are available in several formulations (ie, creams, ointments, lotions, gels, etc). They can be used as part of a general treatment regimen for patients with psoriasis to help reduce itching and desquamation.

Table IX. Recommendations and strength of recommendation for topical tazarotene

Reference number	Recommendations	Strength of recommendation
4.1	Topical tazarotene can be used for the treatment of mild to moderate psoriasis	B
4.2	Topical tazarotene can be used for the treatment of nail psoriasis	B
4.3	The combination of topical tazarotene and NB-UVB has been shown to be effective and allow a reduction in total use of NB-UVB	B
4.4	The use of mid- or high-potency topical corticosteroid in combination with tazarotene for 8-16 weeks is more effective than monotherapy with tazarotene and is recommended for the treatment of mild to moderate psoriasis	A
4.5	The use of topical corticosteroids along with tazarotene is recommended to decrease the duration of treatment as well as increase the length of remission	A

NB-UVB, Narrowband ultraviolet B.

Table X. Level of evidence for topical tazarotene

Recommendation	Reference number	Level of evidence	Studies
Tazarotene for mild to moderate psoriasis	4.1	I-III	102-107
Tazarotene for nail psoriasis	4.2	I-II	114,117,118
Tazarotene and NB-UVB combination	4.3	II	108
Monotherapy (tazarotene) vs combination with mid- to high-potency topical corticosteroid for psoriasis	4.4	I	114,116
Synergistic effect of combination therapy	4.5	I	107,115

NB-UVB, Narrowband ultraviolet B.

Emollients, one type of moisturizer, exert their action by retaining moisture in the stratum corneum. An RCT showed the combination of mometasone plus emollient improved the area of palmoplantar skin affected, desquamation, and symptoms compared with mometasone alone after 4 weeks of treatment.¹¹⁹ Emollients have no known contraindications unless there is hypersensitivity to their ingredients. Recommendations on the use of moisturizers and its supporting evidence can be found in Tables XI and XII.^{119,120}

Risks/harms and benefits. There is a small risk of contact dermatitis with some emollients. Emollients, like any other topical agents, may be inconvenient to regularly apply for patients with a large BSA of involvement. Moisturizers are considered safe during pregnancy and lactation.

General comments. Moisturizers can be safely applied several times a day.

Salicylic acid

Efficacy. Salicylic acid is used as a topical keratolytic agent in the treatment of psoriasis. Its

mechanism of action is believed to involve the reduction of the binding between keratinocytes; it minimizes scaling and softens psoriatic plaques.¹²¹ Topical salicylic acid use for 8 to 16 weeks is recommended for the treatment of mild to moderate psoriasis. Salicylic acid is effective for the treatment of psoriasis, alone or combined with other topical therapies, including corticosteroids and topical immunomodulators.^{52,70,122,123} The improvements in efficacy seen with combination therapy compared with corticosteroid alone is likely due to the increased skin penetration caused by salicylic acid. An open-label study of 10 patients assessed the efficacy of 6% salicylic acid in an ammonium lactate vehicle for the treatment of scalp psoriasis. After 4 weeks of monotherapy, the mean Psoriasis Scalp Severity Index decreased from 15 to 3.¹²³ An RCT with 408 patients with psoriasis revealed that mometasone 0.1% with salicylic acid was superior to mometasone 0.1% ointment after 21 days of twice-daily use for plaques on upper and lower extremities.¹²⁴ Additionally, the combination of tacrolimus with 6% salicylic acid was more effective than salicylic acid plus vehicle.⁵²

Risks/harms and benefits. Systemic absorption and increased risk for salicylate toxicity are higher in patients with renal disease and patients with hepatic disease when treating large BSAs (>20%); therefore, its use should be avoided or used with caution in these groups. Topical salicylic acid should not be applied before UVB phototherapy because it reduces its efficacy.^{125,126} There are inadequate human data available for the use of salicylic acid during pregnancy/lactation.

Topical corticosteroids and salicylic acid. The combination of salicylic acid with topical corticosteroids can be used for the treatment of moderate to severe psoriasis (BSA ≤20%) as well as palmar-plantar psoriasis. Two randomized multicenter studies demonstrated the addition of salicylic acid to mometasone furoate is safe

Table XI. Recommendations and strength of recommendation for emollient

Reference number	Recommendations	Strength of recommendation
5.1	The use of an emollient in conjunction with topical corticosteroids for 4 to 8 weeks can be used to help reduce itching, desquamation, and total body surface area and prevent quick relapse of psoriasis when topical corticosteroids are discontinued	B

and more effective than mometasone alone.^{124,127} High-potency topical corticosteroids can be used in combination with salicylic acid, but caution must be used to ensure only small quantities of the high-strength corticosteroid are used to reduce the potential risk of systemic absorption of the corticosteroid. Recommendations on the use of topical salicylic acid and its supporting evidence can be found in [Tables XIII](#) and [XIV](#).^{52,70,122-124,127}

Anthralin (dithranol)

Efficacy. Anthralin (dithranol) is a polycyclic aromatic hydrocarbon derivative. The exact mechanism of action of anthralin is not fully understood, although it is thought to be mediated by preventing T-lymphocyte activation and promoting keratinocyte differentiation.¹²⁸

Topical anthralin is effective in the treatment of psoriasis.¹²⁹⁻¹³² The recommended treatment for mild to moderate psoriasis is 8 to 12 weeks of topical anthralin starting at 0.1% concentration, with increasing concentration over time as tolerated. Short contact (up to 2 hours per once-daily application) anthralin therapy is recommended to limit adverse effects. Two small RCTs with 12 and 25 psoriasis patients assessed the efficacy of an aqueous gel formulation of anthralin and an anthralin ointment, respectively. After 4 weeks of twice-daily 1-minute treatments, anthralin demonstrated significantly better results than placebo and similar efficacy to topical calcipotriene.^{129,130} An RCT of 106 patients that compared calcipotriene and short-contact dithranol showed no statistically significant difference in the quality of life over 12 weeks between the 2 treatments.¹³¹

Combination treatment of anthralin with excimer laser showed better results than anthralin alone and similar results to the combination of 308-nm laser

Table XII. Level of evidence for emollient

Recommendation	Reference number	Level of evidence	Studies
Emollients in conjunction with topical corticosteroid therapy	5.1	II	119,120

plus topical calcipotriene.¹³² Recommendations on the use of topical anthralin and its supporting evidence can be found in [Tables XV](#) and [XVI](#).¹²⁹⁻¹³²

Risks/harms and benefits. Adverse effects include perilesional erythema, burning, and mild-to-severe staining of the skin. These are improved by using the short-contact application method (up to 2 hours). Application to the face or other highly visible areas should be avoided. There is no evidence of any topical or systemic toxicities related to prolonged anthralin use. No data are available on human milk excretion.

Precaution. Anthralin can temporarily stain the skin, and application to the face or other highly visible areas should be avoided. The use of anthralin on the face and flexures should be avoided.

Coal tar/LCD

Efficacy. Coal tar/LCD, a distillation product from coal, is a heterogeneous mixture of thousands of chemical compounds. Its composition differs between preparations. Coal tar has been used for the treatment of psoriasis for more than a century. The polyaromatic hydrocarbons bind to the aryl hydrocarbon receptor, and tar is known to decrease keratinocyte proliferation by suppressing DNA synthesis. It also suppresses inflammation and may affect immunologic function. Several clinical trials and a systematic review have shown the efficacy of coal tar in the treatment of psoriasis.^{77,78,111,133-138} The use of coal tar preparations is recommended for the treatment of mild to moderate psoriasis. An RCT compared 1% coal tar lotion with 5% coal tar extract among 324 patients with mild to moderate psoriasis. The improvement in Total Sign Score was better in patients treated with 1% lotion than with 5% extract (−10.6%; 95% CI, −20.6% to −0.5%; $P = .04$).¹³³ Another RCT of 60 patients compared LCD 15% solution and calcipotriene 0.005% cream. The LCD group had greater mean reductions in PASI scores than the calcipotriene group at 12 weeks (58% vs 37%; $P < .05$).⁷⁸ Coal tar can also be combined with NB-UVB, resulting in reduction of the time to clearance and improved therapeutic outcome compared with NB-UVB alone.^{137,138} An example of that is Goeckerman therapy, which consists of the application of coal tar and exposure to NB-UVB light.

Table XIII. Recommendation and strength of recommendation for salicylic acid

Reference number	Recommendations	Strength of recommendation
6.1	Topical salicylic acid can be used for 8-16 weeks for the treatment of mild to moderate psoriasis	B
6.2	The combination of salicylic acid with topical corticosteroids can be used for the treatment of moderate to severe psoriasis (body surface area ≤20%)	B

Table XIV. Level of evidence for salicylic acid

Recommendation	Reference number	Level of evidence	Studies
Topical salicylic acid for mild to moderate psoriasis	6.1	I-II	52,70,122-124
Salicylic acid plus topical corticosteroid for psoriasis	6.2	I	124,127

Risks/harms and benefits. The risks of coal tar application include local irritation, folliculitis, contact dermatitis, and phototoxicity. Possible carcinogenicity has remained controversial, but not proven. Dermatologic studies on topical preparations have not revealed an increased risk, but animal and occupational studies document carcinogenicity with prolonged exposures over many years.^{139,140} A retrospective analysis of human use of coal tar preparations during pregnancy has not shown any adverse effects on the fetus, although in animal studies, large doses have been observed to increase the risk of cleft palates, small lungs, and perinatal mortality.^{141,142} Thus, it may be advisable to avoid the use of coal tar preparations during pregnancy and lactation.^{36,143} Coal tar preparations have frequently been used in conjunction with phototherapy. While the application of coal tar 1 day before phototherapy may be helpful, the application just before phototherapy can cause tar pigmentation. Refer to the joint AAD-NPF guideline on phototherapy in reference to Goeckerman therapy.⁹⁰ Recommendations on the use of coal tar and its supporting evidence can be found in [Tables XVII⁹⁰](#) and [XVIII^{77,78,111,133-138,144,145}](#).

Precaution. Coal tar products can stain clothes, and tar odor is present in most preparations, thus reducing patient adherence.

Table XV. Recommendation and strength of recommendation for topical anthralin

Reference number	Recommendation	Strength of recommendation
7.1	Topical anthralin for 8-12 weeks can be used for the treatment of mild to moderate psoriasis. Short contact (up to 2 hours per day) anthralin is recommended to limit adverse side effects	B

Table XVI. Level of evidence for topical anthralin

Recommendation	Reference number	Level of evidence	Studies
Topical anthralin for mild to moderate psoriasis	7.1	I-III	129-132

Topical agents in combination with systemic therapies

Topical agents in combination with biologics. All topical corticosteroids can be used with biologic agents for the treatment of psoriasis. The addition of an ultrahigh-potency (class 1) topical corticosteroid to standard-dose etanercept led to improved efficacy without any increased safety concerns.¹⁴⁶ This advantageous effect of combination therapy at 12 weeks disappeared by 24 weeks.¹⁴⁶ The addition of calcipotriene/betamethasone to standard-dose adalimumab resulted in higher efficacy than adalimumab monotherapy at 4 weeks, but at 16 weeks, there was no difference in efficacy between the 2 groups ([Tables XIX](#) and [XX](#)).^{146,147}

Topical agents in combination with nonbiologic therapies

Topical calcipotriene and methotrexate. The addition of topical calcipotriene to standard-dose methotrexate leads to lower cumulative doses of methotrexate and increased time to relapse after its discontinuation.¹⁴⁸ A multicenter RCT (vehicle-controlled) demonstrated that when calcipotriene was added to weekly methotrexate, calcipotriene decreased the necessary dosing of methotrexate from 9.9 to 6.5 mg per week ($P = .002$) ([Tables XXI](#) and [XXII](#)).¹⁴⁸

Topical agents and cyclosporine. The addition of calcipotriene/betamethasone dipropionate ointment to low-dose cyclosporine (2 mg/kg/d) enhances the clinical response of cyclosporine. An open-label RCT of patients with moderate to severe

Table XVII. Recommendations and strength of recommendation for coal tar

Reference number	Recommendation	Strength of recommendation
8.1	Coal tar preparations are recommended for the treatment of mild to moderate psoriasis	A
8.2	According to the joint AAD-NPF phototherapy guideline, ⁹⁰ there is sufficient evidence to recommend the use of Goeckerman therapy for the treatment of psoriasis	B

AAD, American Academy of Dermatology; NPF, National Psoriasis Foundation.

psoriasis demonstrated that 30 patients given 2 mg/kg/d cyclosporine along with calcipotriene/betamethasone had a significantly higher PASI 75 at 8 weeks of treatment than 30 patients treated with 2 mg/kg/d cyclosporine with emollient placebo ointment (87% vs 37%; $P = .0001$) (Tables XXIII and XXIV).¹⁴⁹

Topical calcipotriene and acitretin. The addition of calcipotriene ointment to the standard dose of acitretin can improve the efficacy of acitretin. A multicenter RCT of 135 adults with severe psoriasis demonstrated a greater rate of clearance and marked improvement in the combination group compared with acitretin alone (67% vs 41%; $P = .006$).⁴ There were no differences in safety between the 2 groups (Tables XXV and XXVI).⁴

Role of patient preferences—with topical agents. The optimal vehicle choice is often the one the patient is most likely to use. For example, hair-bearing areas, such as the scalp, are often successfully treated with solutions, shampoos, foams, oils, gels, or sprays. In general, creams are more cosmetically acceptable than ointments for glabrous skin. Nevertheless, some patients do prefer ointments.

It is recommended that clinicians take into account patient preference when selecting the most appropriate vehicle, recognizing different vehicles may have a different clinical impact on patients and their adherence to treatment. It is important for the health care provider to be aware of the different vehicles available to provide the best option for each patient on a case-by-case basis.

Compounding of topical agents. Compounding by reputable pharmacies of topical agents is frequently used in clinical practice and is beneficial

Table XVIII. Level of evidence for coal tar

Recommendation	Recommendation number	Level of evidence	Studies
Use of coal tar for psoriasis	8.1	I-II	70,71,104,133-138
Goeckerman therapy for psoriasis	8.2	II-III	144,145

in certain patients pending the quality of the ingredients and the quality of the compounding.

This concludes the portion of the AAD-NPF Joint Guideline on care for the management of psoriasis with topical therapy. The following section of this joint guideline will focus on the use of alternative medicine (AM) for the treatment of psoriasis. The workgroup provided their expert opinion on AM therapy and is not part of evidence-based recommendations. Furthermore, the joint guideline also discusses the severity measures of psoriasis used in clinical practice and trials as well as patient-reported outcomes.

II. ALTERNATIVE MEDICINE

AM can be defined as a set of products and practices that are believed to have similar or better healing effects than allopathic medicine. Nevertheless, in many cases, their effectiveness may not have been established using scientific methods or may have not shown similar or superior results compared with conventional medications. AM is not typically part of conventional medical care or has origins outside of usual Western practice and may be desired by, and be of benefit to, a subset of patients. Complementary AM consists of the use of AM together with conventional medical treatment, based on the belief that it improves the effect of medical treatments.

Traditional Chinese medicine

Efficacy. Traditional Chinese medicine is an approach commonly used in China for patients of varying psoriasis severity and includes topical and oral herbs as well as acupuncture and other therapeutic modalities. Herbal methods should only be considered and incorporated if the ingredients within the herbal blends are known and well understood. Acupuncture has been used for the therapy of psoriasis, especially mild to moderate with responses relatively minor.

Several clinical trials have assessed the efficacy of herbal medicine (HM) for the treatment of psoriasis.

Table XIX. Recommendations and strength of recommendation for the combination of topical agents with biologics

Recommendation number	Recommendation	Strength of recommendation
9.1	The addition of an ultrahigh potency (class 1) topical corticosteroid to standard dose etanercept for 12 weeks is recommended for the treatment of moderate to severe psoriasis	A
9.2	The addition of calcipotriene/betamethasone to standard dose adalimumab for 16 weeks is recommended for the treatment of moderate to severe psoriasis to accelerate clearance of psoriatic plaques.	B
9.3	All topical corticosteroids can be used in combination with any biologics for the treatment of moderate to severe psoriasis	C

Table XX. Level of evidence for the combination of topical agents with biologics

Recommendation	Recommendation number	Level of evidence	Studies
Addition of class 1 topical corticosteroid to standard dose etanercept for psoriasis	9.1	I	146
Addition of calcipotriene/betamethasone to standard dose adalimumab for psoriasis	9.2	III	Expert opinion
Topical corticosteroid with biologic for treatment of psoriasis	9.3	III	Expert opinion

Table XXI. Recommendation and strength of recommendation for the combination of topical calcipotriene and methotrexate

Recommendation number	Recommendation	Strength of recommendation
10.1	The addition of topical calcipotriene to standard dose methotrexate therapy is recommended for the treatment of moderate to severe psoriasis. It may lead to lower cumulative doses of methotrexate and increased time to relapse after methotrexate discontinuation	A

Table XXII. Level of evidence for the combination of topical calcipotriene and methotrexate

Recommendation	Recommendation number	Level of evidence	Studies
Calcipotriene and methotrexate for psoriasis	10.1	I	148

A systematic review of topical HM for the treatment of psoriasis found that *Mabonia aquifolium*, indigo naturalis, and *Camptotheca* sp showed anti-inflammatory benefits compared with the vehicle. Adding these topical HMs to conventional

pharmacotherapy appeared to produce additional clinical benefits. Nevertheless, the author mentions the lack of standardization as a weakness of the included studies and states further research is needed to assess the efficacy and safety of these HMs as adjunct therapies for psoriasis.¹⁵⁰ An RCT assessed the efficacy of indigo naturalis extract in oil (lindioil) vs olive oil for the treatment of nail psoriasis. After 12 weeks of twice-daily treatment, there was a significant difference in Nail Psoriasis Severity Index reduction for 1 hand of 48.9% for the lindioil group vs 22.9% for the olive oil group.¹⁵¹

A RCT with 56 patients with psoriasis assessed the efficacy of electrostimulation by intramuscularly placed needles plus ear acupuncture or placebo (minimal acupuncture) twice weekly for 10 weeks. After 10 weeks of treatment, the mean PASI had

Table XXIII. Recommendation and strength of recommendation for combination of topical agents and cyclosporine

Recommendation number	Recommendation	Strength of recommendation
11.1	The addition of calcipotriene/betamethasone dipropionate ointment to low dose (2 mg/kg/d) cyclosporine can be used for the treatment of moderate to severe psoriasis	B

Table XXIV. Level of evidence for the combination of topical agents and cyclosporine

Recommendation	Recommendation number	Level of evidence	Studies
Cyclosporine and calcipotriene/betamethasone dipropionate for psoriasis	11.1	I	¹⁴⁹

Table XXV. Recommendation and strength of recommendation for the combination of calcipotriene and acitretin

Recommendation number	Recommendation	Strength of recommendation
12.1	The addition of calcipotriene to standard dose acitretin is recommended for the treatment of moderate to severe psoriasis.	A

decreased from 9.6 to 8.3 in the active group and from 9.2 to 6.9 in the placebo group ($P < .05$ for both groups), with no statistically significant differences between the 2 groups. The benefit seen with minimal acupuncture may indicate a positive placebo effect from the perception of attention paid to the patient and mere interest in a holistic approach on the part of a practitioner.¹⁵²

Table XXVI. Level of evidence for the combination of calcipotriene and acitretin

Recommendation	Recommendation number	Level of evidence	Studies
Calcipotriene and acitretin for psoriasis	12.1	I	⁴

A single-blind RCT compared “auricular therapy” (pressure and blood-letting puncture of the auricular points on the back of the ear) plus optimized Yinxieling formula with Yinxieling formula alone in 84 patients with psoriasis. Optimized Yinxieling formula is composed of *Radix paeoniae rubra*, *Rhizoma curcumae*, sarcandra, *Radix glycyrrhizae*, *Fructus mume*, *Radix arnebiae*, and *Rhizoma smilacis glabrae*. After 8 weeks of treatment, the PASI reduction in the combination treatment group was 74.4% (32 of 43) compared with the optimized Yinxieling formula alone group (36.6%, $P < .01$).¹⁵³

An open-label RCT with 60 patients with psoriasis using Yin Xie Ping granules vs Xiao Yin Pian (known HM to treat psoriasis as control) found no significant difference between the 2 groups.¹⁵⁴ The clinical improvement determined as cured and markedly effective was achieved by 61.67% and 50% patients in Yin Xie Ping and control group, respectively. Yin Xie Ping is compounded with *Radix rehmanniae*, *Radix angelicae formosanae*, powder of *Carapax eretmochelys*, *Radix paeoniae rubra*, *Calculus bovis artificial*, and *Herba schizonepetae tenuifoliae*. Xiao Yin Pian is compounded with *Radix rehmanniae*, *Cortex moutan*, *Radix paeoniae rubra*, *Sophora flavescens*, honeysuckle, *Radix sappan*, *Arctium lappa*, *Folium isatidis*, and safflower.

A systematic review of studies comparing UVA and UVB phototherapy with and without herbal baths showed that herbal baths appeared to improve response to phototherapy, but the lack of standardization makes results difficult to interpret and replicate.¹⁵⁵ The HM formula used for the bath varied across the 13 studies analyzed. The most frequently used herbs were *Salvia miltiorrhiza* root, *Dictamnus dasycarpus* bark, *Sophora flavescens* root, and *Kochia scoparia* fruit. The HM bath was taken for 20 to 30 minutes before each phototherapy session.

Risks/harms and benefits. Constituent herbs can be difficult to elucidate in Chinese herbal blends, thereby making allergy and toxicity risk difficult to predict. Some formulations of herbal remedies have been found to contain corticosteroids.^{156,157} Topical indigo naturalis must be carefully formulated by a

compounding or integrative pharmacist to minimize the natural purple staining effect of the crude extract.

Exclusions. There is little information on the effects of HM for psoriasis treatment during pregnancy or lactation. Because of the unknown effects on the fetus or infant, they should be avoided during pregnancy and breastfeeding and if there is a known allergy to prevent potential toxicity from herbal blends.

Role of patient preferences. Many patients undergo acupuncture for a variety of health reasons. Several insurance companies reimburse for acupuncture. Interest on the part of patients is high.¹⁵⁸

General comments. Traditional Chinese medicine is by definition an individualized medical practice based on each patient's constitution and therefore is difficult to study in an aggregate model. Additionally, the lack of standardized clinical trials makes it very difficult to clearly assess the efficacy of these treatments. Understanding traditional Chinese medicine requires an intense background in herbology, which is lacking in traditional allopathic medical curricula.

Aloe vera

Efficacy. *Aloe vera* (AV) is a succulent plant species of the genus *Aloe*. Its use has been documented in medicine for centuries. In patients who are not allergic to AV, topical AV may be efficacious for mild psoriasis. An RCT with 60 patients with psoriasis comparing thrice-daily application of AV vs placebo for 4 weeks reported 83.3% cure rate (complete clearance) in the AV group vs 6.6% in the placebo group.¹⁵⁹ A double-blind RCT with 40 patients assessing AV vs placebo showed no difference between the 2 groups after 4 weeks of twice-daily application.¹⁶⁰ Furthermore, the clinical score sum of erythema, infiltration, and desquamation decreased in 72.5% in the AV-treated areas compared with 82.5% in placebo-treated areas after 12 weeks.¹⁶⁰ Despite the placebo effect being elevated and higher than that of AV, the clinical effect of AV was not negligible. Nevertheless, it should be noted that AV might not be better than just an emollient. Additionally, topical and oral use of AV can cause skin irritation, hives, cramping, and diarrhea to those who are allergic to other plants related to the lily family, for example, onion and tulips.^{161,162}

Risks/harms and benefits. There is a risk of contact dermatitis with AV use.

Contraindication. Treatment should not be used in patients who are allergic to AV.

Role of patient preferences. For patients who are interested in trying a plant-based treatment for their mild psoriasis, AV may be a reasonable consideration.

St John's wort

Efficacy. Topical St John's wort may improve mild psoriasis, but its compounding is not standardized or well-studied enough to recommend its use. There is limited literature on this subject. A split-body study with compounded topical St John's wort cream showed a significant modified PASI reduction at 4 weeks compared with vehicle alone ($P < .04$).¹⁶³ This study demonstrated a reduction in erythema, lesional thickness, and scaling over 4 weeks.

Risks/harms and benefits. Owing to St John's wort photosensitizing effect, caution exists for burns and sunburns, especially for psoriasis patients undergoing phototherapy.

Exclusions. St John's wort is photosensitizing when administered topically and orally. Caution should be exercised in patients with a history of skin cancer or continued heavy sun exposure, or both, including phototherapy. Safety in pregnant and nursing women is unknown.

Role of patient preferences. Considering an increasing number of patients asking about nonprescription and natural options for psoriasis, further studies are required to better assess the role of St John's wort in psoriasis.

General comments. Because St John's wort is a supplement that is generally used for potential antidepressive effects, a potential therapeutic role in psoriasis may also exist in the area of stress reduction if taken orally.

Fish/omega-3 oil

Efficacy. Fish oil may exert an anti-inflammatory effect via inhibition of inflammatory eicosanoid formation. Fish oil/omega-3 fatty acid oral supplementation has been useful as a monotherapy for psoriasis.^{164,165} Oral fish oil supplementation may augment the effects of topical, oral-systemic, and phototherapy for chronic plaque psoriasis. It can be considered as an additional supplement in patients with chronic plaque psoriasis.¹⁶⁶⁻¹⁷⁰ Fish oil can be useful as adjuvant therapy for treatments, including acitretin, cyclosporine, and NB-UVB.^{171,172} A randomized 12-week open study revealed that etretinate and eicosapentaenoic acid supplementation for patients with chronic stable plaque psoriasis had better and more rapid improvement compared with etretinate alone.¹⁷³

Risks/harms and benefits. Owing to contaminants, fish oil supplementation can cause mercury

poisoning or accumulation of other toxins such as dioxins and polychlorinated biphenyls.¹⁷⁴⁻¹⁷⁶

Exclusions. Caution should be exercised in pregnant women. Patients should be instructed to select supplements that are free of mercury, dioxin, and polychlorinated biphenyls. Fish oil can reduce platelet aggregation, but this effect did not increase bleeding risk during or after surgery in RCTs.^{177,178}

Role of patient preferences. Considering an increasing number of patients frequently asking about nonprescription and natural treatment options for psoriasis, further studies are required to better assess the role of fish oil supplementation/omega-3 fatty acids in psoriasis.

Vitamin D supplementation

Efficacy. While topical vitamin D analogues have benefit in psoriasis, oral supplementation does not directly improve disease activity at dosages that avoid hypercalcemia and calciuria.¹⁷⁹⁻¹⁸³ Therefore, oral vitamin D supplementation is not recommended for the treatment of psoriasis.¹⁸³

Risks/harms and benefits. Excess vitamin D supplementation may lead to hypercalcemia.

Precaution. The studies reviewed here do not include pregnant or lactating women, or children.

Role of patient preferences. Many patients ask about the overall role of vitamin D in skin health. Rather than adding oral vitamin D supplementation, topical therapy with vitamin D agents is effective for the treatment of psoriasis.

Curcumin

Efficacy. Curcumin is the active chemical in the spice turmeric. Curcumin modulates T-helper type 22 cell activity and decreases epidermal proliferation via inhibition of adenosine-5'-triphosphate-phosphorylase b phosphotransferase activity, similar to topical vitamin D₃ analogues.¹⁸⁴ Piperine derived from black pepper greatly enhances the absorption of dietary curcumin.¹⁸⁵ While there is limited literature on this subject, oral curcumin supplementation may benefit patients with psoriasis as adjunctive therapy.

Risks/harms and benefits. Curcumin has low toxicity but poor bioavailability.

Role of patient preferences. Patients increasingly ask about nonprescription or natural options for psoriasis. Further studies are required to better assess the role of curcumin in psoriasis.

Zinc

Efficacy. There is limited literature on the efficacy of zinc for the treatment of psoriasis. Oral zinc supplementation did not independently improve

psoriasis severity (PASI scores) and therefore is not recommended.¹⁸⁶

Risks/harms and benefits. Oral zinc has been associated with headaches, nausea, vomiting, decreased appetite, diarrhea, and abdominal cramps.¹⁸⁷ In high doses with prolonged use, oral zinc can have more severe adverse effects such as low copper, anemia, leukopenia, neutropenia, and gastrointestinal ulcers.¹⁸⁷

Role of patient preferences. Patients are increasingly interested in taking oral supplements. Further studies are required to better assess the role of zinc supplementation in psoriasis.

Gluten-free diet

Efficacy. Gluten is a group of proteins present in various cereal grains that are associated with hypersensitivity and celiac disease in certain patients. A small percentage (4%-14%) of patients with moderate to severe plaque psoriasis have a higher incidence of celiac disease and therefore should be asked about gastrointestinal symptoms of celiac disease.¹⁸⁸⁻¹⁹¹ If patients have a positive serology for the disease or have gastrointestinal symptoms of celiac disease, consultation with a gastrointestinal physician to confirm celiac disease with small intestine biopsy and manage the disease is advised. Adherence to a gluten-free diet is part of the treatment plan only for patients with confirmed celiac disease.¹⁹¹⁻¹⁹³

Patients testing positive to celiac antibodies may not benefit from a strict gluten-free diet in terms of PASI improvement, because they may not have actual celiac disease. The diagnosis of celiac disease is not just based on symptoms and serology, and patients should be referred to a gastroenterologist for diagnosis and management. For patients who are already following restricted diets (vegetarian, vegan, nut-free, etc.) due to personal choice or other medical conditions (including food allergies) and are now planning to eliminate gluten, consultation with a nutritionist is strongly suggested to optimize nutrition and assist in meal planning. A gluten-free diet is inadvisable from a psoriasis treatment perspective unless the patient has a confirmed diagnosis of celiac disease.

Role of patient preferences. Patients often ask about the role of diet in skin health, and many would be interested in incorporating a gluten-free diet if applicable and potentially beneficial. Others would find this diet a detriment to their quality of life.

Hypnosis

Efficacy. Hypnosis is a state characterized by focused attention and an increased capacity to

respond to suggestions. Hypnosis should be considered a therapeutic adjunct for highly hypnotizable patients with mild to moderate psoriasis. However, there is limited literature on this subject. A small pilot trial in 11 patients with psoriasis showed a significant improvement in the PASI score and attainment of PASI 75 compared with neutral hypnosis after 3 months of weekly hypnosis ($P < .001$).¹⁹⁴

General comments. These recommendations would not apply to patients who are not highly hypnotizable. Access to a trained hypnotherapist would limit the ability to incorporate this therapy.

Role of patient preferences. Patients must be interested in and amenable to hypnosis for optimal benefit. Further studies are required to better assess the role of hypnosis in psoriasis.

Stress reduction

Efficacy. Stress reduction includes a wide spectrum of techniques aimed at controlling a person's stress level. Meditation as a form of stress reduction can have a positive impact on the severity of symptoms in some patients with psoriasis. Therefore, it can be discussed as adjunctive therapy with interested patients. A small study assessing different meditation techniques as adjunctive therapy in patients with mild to moderate psoriasis treated with topical therapies showed improvement of psoriasis symptoms after 12 weeks compared with no adjunctive treatment.¹⁹⁵ There is evidence that guided mindfulness meditation improves outcomes in patients with moderate psoriasis qualifying for phototherapy.¹⁹⁶ Biofeedback and relaxation techniques (progressive and suggestive) may improve symptoms in some patients with mild psoriasis and should also be considered for adjunctive therapy.¹⁹⁷ Psychologic interventions in the form of stress reduction techniques, cognitive behavioral therapy, and guided imagery can improve psoriasis severity and should be discussed with all interested patients.¹⁹⁸ Data are limited on this subject, and further research is needed.

Risks/harms and benefits. While studies are limited and data are lacking, individual treatment responses are positive, with little to no adverse effect of these adjunctive recommendations (expert opinion).

Work and other time constraints may be a limiting factor for some patients to engage in a guided meditation or relaxation strategies, but interested patients can be taught a self-guided practice that can be tailored to any schedules.

Biofeedback is time-consuming and requires specialized equipment.

Role of patient preferences. Patients' interest in, and receptiveness to, mindfulness meditation practices may influence the degree of therapeutic efficacy. Further studies are required to assess the role of stress reduction in psoriasis. Supplementary statements for complimentary alternative medicine can be found in [Table XXVII](#).[†]

This concludes the portion of the AAD-NPF joint guideline on AM. The following section of this joint guideline will focus on severity measures for psoriasis.

III. PSORIASIS SEVERITY MEASURES

Body surface area

Recommendations. BSA, one of the most commonly used measures in clinical and research dermatology, is recommended to assess the severity of psoriasis as well as the response to treatment in the clinical setting.²¹³⁻²¹⁷ It is calculated by using the area from the wrist to the fingers and thumb of the hand closed together to represent ~1% of the patient's BSA.²¹⁸ Its use can be simplified by rounding up the percentage of BSA corresponding to different parts of the body. The head and neck, upper extremities, trunk, and lower extremities (including buttocks) correspond to approximately 10%, 20%, 30%, and 40% of the BSA, respectively. Refer to *AAD pay-for-performance Measure 410* for further details.²¹⁸

Patient preferences play a primary role in determining the final treatment target and treatment. A full discussion should be offered to the patient regarding the treatment options and expected benefits, risks, and outcomes in order to facilitate a shared decision-making approach.

The reassessment of disease severity and response to therapy can be performed regularly and adjustments to therapy made as necessary. In particular, if the patient is dissatisfied with clinical responses, a different therapy should be considered. Individual patient preferences and comorbidities are important in the final treatment plan. If a patient is satisfied with their results, they should continue treatment even if it does not meet the target or recommended improvement. Recommendations on the use of BSA and its supporting evidence can be found in [Tables XXVIII](#) and [XXIX](#).

Pitfalls (or limitations) in assessment. BSA can be overestimated, particularly by untrained providers.²¹⁹⁻²²³ Nevertheless, BSA assessment has good

[†]References 150-155,159,160,163,164,166-168,170-173,179,182,184, 186,188-212.

Table XXVII. Supplementary statements for complementary alternative medicine*

Therapy	Statement	Studies
Traditional Chinese medicine (TCM)*	<p>Herbal methods should only be considered and incorporated if herbal blends are well understood and if working with practitioners experienced in dermatology and in TCM</p> <p>Acupuncture may have a therapeutic effect on chronic plaque psoriasis and can be considered as adjunctive therapy in psoriasis based on patient interest and practice availability</p> <p>Risk/harm and benefits</p> <ul style="list-style-type: none"> • Topical indigo naturalis must be carefully formulated by a compounding or integrative pharmacist to avoid the natural purple staining effect of the crude extract • Constituent herbs can be difficult to elucidate in Chinese herbal blends, thereby making allergy and toxicity difficult to predict • The benefit seen with “sham” acupuncture may indicate a positive placebo effect from the perception of attention paid to the patient and mere interest in a holistic approach on the part of a practitioner <p>Exclusions</p> <ul style="list-style-type: none"> • Safety in pregnancy and breastfeeding are unknown. Potential allergy and toxicity risk exist from undifferentiated herbal blends 	150-155,199-202
<i>Aloe vera</i> *	<p>In patients who are not allergic, topical <i>Aloe vera</i> may have efficacy in the treatment of mild psoriasis</p> <p>Risk/harms and benefits</p> <ul style="list-style-type: none"> • There is a risk of contact dermatitis in patients who use <i>Aloe vera</i> <p>Exclusions</p> <ul style="list-style-type: none"> • Treatment should not be used in patients who are allergic to <i>Aloe vera</i> 	159,160
St John’s wort*	<p>Topical St John’s wort may lower the PASI score but is not standardized, commercially available, or well studied enough to recommend its use</p> <p>Risk/harms and benefit</p> <ul style="list-style-type: none"> • Owing to the photosensitizing effect, caution exists for burns and sunburns, especially for psoriasis patients undergoing phototherapy <p>Exclusions</p> <ul style="list-style-type: none"> • St John’s wort is known to be photosensitizing if taken orally, and this same consideration exists for topical administration. Caution should be exercised in patients with a history of skin cancer and/or continued heavy sun exposure, including phototherapy. Safety in pregnant and nursing women is unknown 	163
Fish oil*	<p>Fish oil/omega-3 fatty acid supplementation is not useful as monotherapy, but may augment the effects of other topical and oral or systemic therapies and phototherapy for chronic plaque psoriasis and may be considered in those patient populations</p> <p>Risk/harms and benefits</p> <ul style="list-style-type: none"> • Owing to contaminants, fish oil supplementation can cause mercury poisoning or accumulation of other toxins such as dioxins and polychlorinated biphenyls (PCBs) <p>Exclusions</p> <ul style="list-style-type: none"> • Caution should be exercised in pregnant women. Patients should be instructed to select supplement sources that are free of mercury, dioxin, and PCBs. The risk of bleeding with fish oil has been generally determined to be not real 	164,166-168, 170-173,203,204

Continued

Table XXVII. Cont'd

Therapy	Statement	Studies
Vitamin D supplementation*	<p>Although it is established that topical vitamin D analogues have benefit in psoriasis, oral supplementation does not directly improve disease activity at dosages that avoid hypercalcemia and calciuria</p> <p>Risk/harms and benefits</p> <ul style="list-style-type: none"> Excess vitamin D supplementation may lead to toxicity in the form of hypercalcemia <p>Exclusions</p> <ul style="list-style-type: none"> Role of vitamin D oral supplementation in pregnant/lactating women or children not included 	179,182,205,206
Curcumin*	Oral curcumin supplementation may benefit patients with psoriasis of varying severity, as adjunctive therapy	184,207-209
Zinc*	Oral zinc supplementation does not improve PASI scores	186
Gluten-free diet*	<p>Patients with moderate to severe plaque psoriasis may, but not always, have a higher incidence of celiac disease and therefore should be asked about GI symptoms of celiac disease. If identified positive, consultation with GI physician for treatment and management of the disease is advised. Further, adherence to a gluten-free diet is suggested to be part of the treatment plan only for patients diagnosed with celiac disease</p> <p>Risk/harm and benefits</p> <ul style="list-style-type: none"> Patients testing positive to celiac antibodies may benefit from a strict gluten-free diet in terms of PASI improvement, but also may not. A trial period of 3 months should be considered. Gluten-free diets are restrictive and can impact the quality of life <p>Exclusions</p> <ul style="list-style-type: none"> For patients who are already following restricted diets (vegetarian, vegan, nut-free, etc) due to personal choice or food allergies and are now planning to eliminate gluten, a nutritionist should be consulted in order to best plan meals and avoid nutritional deficiencies 	188-193,210-212
Hypnosis*	Hypnosis can be discussed with and incorporated as a therapeutic adjunct for highly hypnotizable patients with mild to moderate psoriasis	194
Stress reduction*	<p>Meditation as a form of stress reduction can have a positive impact of severity of symptoms in some patients with psoriasis and therefore could be discussed as adjunctive therapy with interested patients</p> <p>Mindfulness meditation (guided) improves outcomes in patients with moderate psoriasis qualifying for phototherapy</p> <p>Biofeedback and relaxation techniques (progressive and suggestive) may improve symptoms in some patients with mild psoriasis and should be considered for adjunctive therapy</p> <p>Psychologic interventions in the form of stress reduction techniques, cognitive behavioral therapy, and guided imagery can improve psoriasis severity and should be discussed with all interested patients</p> <p>Risk/harm and benefits</p> <ul style="list-style-type: none"> Work and other time constraints may be a limiting factor for some patients to engage in a guided meditation or relaxation strategies but interested patients can be taught a self-guided practice which can be tailored to any schedule Biofeedback is time consuming and requires specialized equipment 	195-198
Other AM therapies	Cannabis and cannabinoids are not infrequently used by patients. Not enough literature is available to justify their use	

AM, Alternative medicine; GI, gastrointestinal; PASI, Psoriasis Area and Severity Index.

*Supporting suggestions are not evidence based.

Table XXVIII. Recommendation and strength of recommendation for body surface area (BSA) severity measure

Recommendation number	Recommendation	Strength of recommendation
13.1	BSA measurement of involved skin is recommended as an important measure of psoriasis severity to risk stratify patient for future comorbidities and to assess response to treatment	B

Table XXIX. Level of evidence for body surface area (BSA) severity measure

Recommendation	Recommendation number	Level of evidence	Studies
BSA for severity assessment of psoriasis	13.1	III	Expert opinion

intra-rater reliability.^{214,224} The BSA measurement is a provider assessment tool. It does not take into account location on the body, clinical characteristics of the plaques, symptoms, or quality of life issues.

Psoriasis area and severity index

Recommendations. PASI assesses 3 plaque issues—erythema, induration, and scaling—plus the BSA affected and provides a severity score ranging from 0 to 72. In general, a score of ≥ 10 is considered moderate to severe psoriasis.²¹⁸ Refer to *AAD pay-for-performance Measure 410* for further details.²¹⁸ PASI is recommended as a measure of psoriasis severity and response to treatment for moderate to severe psoriasis primarily in clinical trials. PASI is primarily a research tool, and its use in clinical practice is infrequent.^{215,216,225-229}

Pitfalls (or limitations) in assessment. Various studies have revealed that PASI has reproducible inter-rater and intra-rater reliability.²³⁰⁻²³² Rater experience reduces the variation in the scores.^{233,234} The delta of mean PASI and the delta of mean Dermatology Life Quality Index (DLQI), a quality of life assessment tool designed for dermatologic conditions, are highly correlated and showed improvement over a prolonged period of time (6.5 years) when treated with biologics.²³⁵ PASI is

Table XXX. Recommendation and strength of recommendation for Psoriasis Area and Severity Index (PASI) severity measure

Recommendation number	Recommendation	Strength of recommendation
14.1	PASI is a commonly used outcome measure in clinical trials. However, it is seldom used in clinical practice to assess psoriasis severity	B

Table XXXI. Level of evidence for the Psoriasis Area and Severity Index (PASI) severity measure

Recommendation	Recommendation number	Level of evidence	Studies
PASI severity assessment tool	14.1	III	^{215,216,225-228}

responsive to varying degrees of improvement in psoriasis.²³⁶ Additionally, PASI is more strongly correlated with clinical response to initiating biologic therapy than DLQI.^{237,238} Nevertheless, PASI is not accurate for mild psoriasis, defined as below 3% BSA affected. The average patient with psoriasis will not have BSA measurements as high as those in clinical trials and research. Furthermore, PASI is not ideal for measuring certain aspects of the disease such as nail, palmoplantar, and genital psoriasis. PASI is not an easily accessible tool to use due to time intensiveness. Thus, PASI is not a frequently used tool in clinical practice.

General comments. The PASI is a provider assessment tool. PASI has significant evidence as a useful tool in research settings but does not take into account symptoms or quality of life issues. Recommendations on the use of PASI and its supporting evidence can be found in [Tables XXX and XXXI](#).^{215,216,225-228}

Physician Global Assessment

Recommendations. The PGA is a scoring system that uses erythema, induration, and scaling. It is suggested as an important measure to assess psoriasis severity and response to treatment.^{215,232,233,236,239,240} There are several different PGA versions, with most severity scores ranging from 0 to 4 or 0 to 5.²¹⁸ In many clinical trials and research, PGA is used as a primary end point, but

Table XXXII. Recommendation and strength of recommendation for the Physician Global Assessment (PGA) severity measure

Recommendation number	Recommendation	Strength of recommendation
15.1	PGA measurement of psoriasis is recommended as an important measure to assess psoriasis severity	B

Table XXXIII. Level of evidence for Physician Global Assessment (PGA) severity measure

Recommendation	Recommendation number	Level of evidence	Studies
PGA for severity assessment of psoriasis	15.1	I-III	215,232,233, 236,239,240

its use in clinical practice, while potentially valuable, is infrequent.

The reassessment of disease severity and response to therapy can be performed at intervals and adjustments to therapy as necessary. Refer to *AAD pay-for-performance Measure 410* for further details.²¹⁸

Individual patient preferences and comorbidities are important regarding the final treatment plan. If a patient is satisfied with their results, they should be allowed to continue treatment even if it does not meet the target or recommended improvement.

Pitfalls (or limitations) in assessment. PGA has reproducible inter-rater and intra-rater reliability and validity.^{232,233,240} PGA is responsive to varying degrees of clinical improvement.²³⁸ Additionally, PGA and Lattice System-PGA do not require significant experience to achieve reliable results.²³³ Plaque quality/morphology does not account for the BSA or the widespread nature of the disease. This is a limitation of the PGA systems.

General comments. The PGA assessment tool is a relatively simple tool to grade and use. It may represent a static measure of the physician's impression at a single point or a dynamic measure in which the physician assesses global improvement from baseline. The PGA does not take into account symptoms or quality of life issues. Recommendations on the use of PGA and its supporting evidence can be found in *Tables XXXII* and *XXXIII*.^{215,232,233,236,239,240}

Table XXXIV. Recommendation and strength of recommendation for Physician Global Assessment (PGA) × body surface area (BSA) severity measure

Recommendation number	Recommendation	Strength of recommendation
16.1	PGA × BSA is recommended as an important measure of psoriasis severity	B

Table XXXV. Level of evidence for Physician Global Assessment (PGA) × body surface area (BSA) severity measure

Recommendation	Recommendation number	Level of evidence	Studies
PGA × BSA for the assessment of psoriasis severity	16.1	II	241-243

PGA × BSA

Recommendations. PGA × BSA can be used as a measure of psoriasis severity and response to treatment. It is not commonly used, although a few dermatologists do use it in clinical practice.

Individual patient preferences and comorbidities are important regarding the final treatment plan. As such, if a patient is satisfied with their results, they should be allowed to continue treatment even if it does not meet the target or recommended improvement. Recommendations on the use of PGA × BSA and its supporting evidence can be found in *Tables XXXIV* and *XXXV*.²⁴¹⁻²⁴³

Pitfalls (or limitations) in assessment. BSA can be overestimated, particularly by untrained providers.²¹⁹⁻²²³ Nevertheless, BSA assessment has good intra-rater reliability.^{214,224} PGA has reproducible inter-rater and intra-rater reliability and validity.^{232,233,240} PGA is responsive to varying degrees of clinical improvement.²³⁶ The BSA measurement is a provider assessment tool. It does not take into account location on the body, clinical characteristics of the plaques, symptoms, or quality of life issues. Furthermore, the combination of 2 measures adds an extra step that could be detrimental for the practical use of this tool in the clinical setting.

Psoriasis Symptom Inventory

Recommendations. The Psoriasis Symptom Inventory (PSI) is a new patient-reported outcome that has been validated in clinical studies and has the potential to be used in clinical practice.²⁴⁴⁻²⁴⁸ The PSI

Table XXXVI. Recommendation and strength of recommendation for Psoriasis Symptom Inventory (PSI) severity measure

Recommendation number	Recommendation	Strength of recommendation
17.1	The PSI is recommended as an important patient-reported measure of psoriasis severity with utility in clinical trials. PSI is a new quality of life instrument and has potential to be used in clinical practice and clinical trials	C

measures the severity of 8 psoriasis signs and symptoms: itch, redness, scaling, burning, stinging, cracking, flaking, and pain. Each item is rated on a scale of 0 to 4, yielding a total score ranging from 0 to 32.

Pitfalls (or limitations) in assessment. As a patient-reported outcome, the PSI relies on patients being willing and able to complete the assessment. For patients with cognitive impairment, the PSI may not be feasible or reliable.

General comments. There are paper versions of the PSI available for patient use. Recommendations on the use of PSI and its supporting evidence can be found in [Tables XXXVI](#) and [XXXVII](#).^{244,247}

Dermatology Life Quality Index

Recommendations. The DLQI is a 10-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. The DLQI score ranges from 0 to 30. It is a self-reported measure of psoriasis that is recommended to assess psoriasis severity and response to treatment with utility in clinical trials.²¹⁸ Refer to the *AAD pay-for-performance Measure 410* for further details.²¹⁸ DLQI is used in more than 40 different skin conditions and is not a specific measurement tool for psoriasis.^{215,216,225-228,249-253}

Pitfalls (or limitations) in assessment. As a patient-reported outcome, the DLQI relies on patients being willing and able to complete the assessment. For patients with cognitive impairment, the DLQI may not be feasible or reliable.

General comments. The DLQI is a patient-reported severity measure used in more than 40 different skin conditions and in the majority of clinical trials in moderate-severe psoriasis.²¹⁸ It is

Table XXXVII. Level of evidence for Symptom Inventory (PSI) severity measure

Recommendation	Recommendation number	Level of evidence	Studies
PSI for severity assessment of psoriasis	17.1	I-II	244-247

Table XXXVIII. Recommendation and strength of recommendation for the Dermatology Life Quality Index (DLQI) severity measure

Recommendation number	Recommendation	Strength of recommendation
18.1	DLQI measurement of psoriasis is recommended as an important measure of psoriasis severity with utility in clinical trials and is seldom used in clinical practice	B

readily used in more than 80 countries and available in more than 85 languages. Recommendations on the use of DLQI and its supporting evidence can be found in [Tables XXXVIII](#) and [XXXIX](#).^{218,225,226,249-253}

Pruritus assessment

Recommendations. Pruritus is a significant symptom of psoriasis and is often under-recognized. Itch severity assessment is recommended for patients whose psoriasis causes significant pruritus because it can have a major impact on a patient's quality of life. Several tools are available to assess this subjective symptom.²⁵⁴⁻²⁷⁰ Nevertheless, at this time there is no recommendation on which tool should be used due to limited evidence. The visual analog scale (VAS) and numeric rating scale (NRS) are 2 of the most commonly used pruritus assessment tools. When assessing patients with these 2 scales, the minimal clinically important difference should be 3 to 4 points for a change to be considered meaningful. Recommendations on the use of pruritus assessment and its supporting evidence can be found in [Tables XXXX](#) and [XXXIX](#).²⁵⁴⁻²⁷³

CONCLUSION

There is no one measure to completely determine a patient's quality of life. Some patients may have a

Table XXXIX. Level of evidence for the Dermatology Life Quality Index (DLQI) severity measure

Recommendation	Recommendation number	Level of evidence	Studies
DLQI is a research tool used in clinical trials	18.1	II-III	225,226, 249-253

Table XXXX. Recommendation and strength of recommendation for pruritus assessment severity measure

Recommendation number	Recommendation	Strength of recommendation
19.1	Pruritus is a significant symptom of psoriasis. An itch severity assessment is recommended to appropriately assess the degree of pruritus when present	B

low severity score, but the affected area may be in a very sensitive location such as the face or hands. This may require escalating the treatment used to treat psoriasis depending on patient preference. Therefore, it is important to work with the patient to determine their satisfaction with the treatment. Similarly, some patients may not be comfortable with certain methods of administration. In these cases, it is also important to work with the patient to determine a treatment modality they are comfortable with. Some patients, for example, may not like using needles; therefore, any treatment relying on needles for self-administration may not be as effective for the patient. Working with the patient will increase adherence to the treatment protocol. There may also be cases in which the patient is satisfied with a less than “clear” outcome. In these cases, it would be necessary to work with the patient to determine what outcome they are satisfied with based on their preferences.

We thank our medical librarian, Charniel McDaniels, MS, and our specialist, David A. Castillo, BS, for helping with search strings, evidence table generation, and the manuscript publication process. During the development of this guideline, Michael Siegel served as a patient representative for the National Psoriasis Foundation.

Table XXXXI. Level of evidence for pruritus assessment severity measure

Recommendation	Recommendation number	Level of evidence	Studies
Itch severity assessment for patients with psoriasis	19.1	II-III	254-270

REFERENCES

- Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients [published correction appears in *J Am Acad Dermatol*. 2020;82(3):574]. *J Am Acad Dermatol*. 2020;82(1):161-201.
- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. *J Am Acad Dermatol*. 2014;70(3):512-516.
- National Center for Complementary and Integrative Health. Complementary, Alternative, or Integrative Health: What's In a Name? NCCIH Clearinghouse. Available at: <https://nccih.nih.gov/health/integrative-health>; 2019. Accessed October 1, 2019.
- van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. *Br J Dermatol*. 1998;138(1):84-89.
- Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. *Arch Dermatol*. 1985; 121(1):63-67.
- Bolognia J, Schaffer JV, Cerroni L. *Dermatology*. 4th ed. Philadelphia: Elsevier; 2018.
- Gabros S, Zito PM. Topical corticosteroids. In: *StatPearls*. Treasure Island (FL); 2019.
- Jacob SE, Steele T. Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. *J Am Acad Dermatol*. 2006;54(4):723-727.
- Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. *J Am Acad Dermatol*. 1991;25(6 Pt 2): 1170-1174.
- Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. *J Cutan Med Surg*. 2003;7(3):185-192.
- Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. *Int J Dermatol*. 2002;41(5):269-274.
- Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. *J Dermatolog Treat*. 2003;14(1):8-13.
- Keegan BR. Desoximetasone 0.25% spray for the relief of scaling in adults with plaque psoriasis. *J Drugs Dermatol*. 2015;14(8):835-840.
- Savin RC. Desoximetasone—a new topical corticosteroid: short-and long-term experiences. *Cutis*. 1978;21(3):403-407.

15. Olsen EA. Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis. *Cutis*. 1996; 57(2 Suppl):57-61.
16. Pauporte M, Maibach H, Lowe N, et al. Fluocinolone acetonide topical oil for scalp psoriasis. *J Dermatolog Treat*. 2004;15(6):360-364.
17. Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U. Betamethasone valerate foam for treatment of nonscalp psoriasis. *J Cutan Med Surg*. 2001;5(4):303-307.
18. James M. A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis. *Cutis*. 2001;67(4 Suppl): 2-9.
19. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. *Br J Dermatol*. 2002;146(3):351-364.
20. Mason AR, Mason JM, Cork MJ, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. *Br J Dermatol*. 2013;169(3):519-527.
21. Richards RN. Update on intralesional steroid: focus on dermatoses. *J Cutan Med Surg*. 2010;14(1):19-23.
22. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol*. 2009; 60(6):962-971.
23. Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. *Indian J Dermatol Venereol Leprol*. 2010;76(6):634-644.
24. Kenalog®-10 Injection (triamcinolone acetonide injectable suspension, USP) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012041s045lbl.pdf. Accessed April 23, 2020.
25. Abraham A, Roga G. Topical steroid-damaged skin. *Indian J Dermatol*. 2014;59(5):456-459.
26. Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. *J Eur Acad Dermatol Venereol*. 2012;26(Suppl 3):47-51.
27. Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H. Femoral head osteonecrosis after long-term topical corticosteroid treatment in a psoriasis patient. *J Dermatol*. 2012; 39(10):887-888.
28. el Maghraoui A, Tabache F, Bezza A, Ghafir D, Ohayon V, Archane MI. Femoral head osteonecrosis after topical corticosteroid therapy. *Clin Exp Rheumatol*. 2001;19(2):233.
29. Malec-Milewska M, Sekowska A, Koleda I, Horosz B, Guc M, Jastrzebski J. Sympathetic nerve blocks for the management of postherpetic neuralgia-19 years of pain clinic experience. *Anaesthesiol Intensive Ther*. 2014;46(4):255-261.
30. Rigopoulos D, Gregoriou S, Daniel CR Iii, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. *Dermatology*. 2009;218(4):338-341.
31. Garrett HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. *Clin Exp Ophthalmol*. 2004;32(2):224-226.
32. Day A, Abramson AK, Patel M, Warren RB, Menter MA. The spectrum of oculocutaneous disease: part II. Neoplastic and drug-related causes of oculocutaneous disease. *J Am Acad Dermatol*. 2014;70(5):821.e-821.e19.
33. Andersen YMF, Egeberg A, Ban L, et al. Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts. *Diabetes Care*. 2019;42(6):1095-1103.
34. Clobex® [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021535Orig1s003,%20021644Orig1s003lbl.pdf. Accessed October 17, 2019.
35. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. *Cochrane Database Syst Rev*. 2015;10:CD007346.
36. De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. *Helv Paediatr Acta*. 1983;38(2):185-189.
37. Chi CC, Wang SH, Kirtschig G. Safety of topical corticosteroids in pregnancy. *JAMA Dermatol*. 2016;152(8):934-935.
38. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. *J Am Acad Dermatol*. 2014;70(3):417.e1-417.e10. quiz 427.
39. Hudson CP, Kempers S, Menter A, et al. An open-label, multicenter study of the efficacy and safety of a week-day/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. *Cutis*. 2011;88(4):201-207.
40. Ito K, Koga M, Shibayama Y, Tatematsu S, Nakayama J, Imafuku S. Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis. *J Dermatol*. 2016; 43(4):402-405.
41. Lavaud J, Mahe E. Proactive treatment in childhood psoriasis. *Ann Dermatol Venereol*. 2020;147(1):29-35.
42. Wu JJ, Lynde CW, Kleyn CE, et al. Identification of key research needs for topical therapy treatment of psoriasis—a consensus paper by the International Psoriasis Council. *J Eur Acad Dermatol Venereol*. 2016;30(7):1115-1119.
43. Fisher DA. Adverse effects of topical corticosteroid use. *West J Med*. 1995;162(2):123-126.
44. du Vivier A. Tachyphylaxis to topically applied steroids. *Arch Dermatol*. 1976;112(9):1245-1248.
45. Kircik L, Lebwohl MG, Del Rosso JQ, Bagel J, Stein Gold L, Weiss JS. Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. *J Drugs Dermatol*. 2013;12(12):1404-1410.
46. Stein Gold L, Jackson JM, Knuckles ML, Weiss JS. Improvement in extensive moderate plaque psoriasis with a novel emollient spray formulation of betamethasone dipropionate 0.05. *J Drugs Dermatol*. 2016;15(3):334-342.
47. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. *Int J Dermatol*. 1999;38(8):628-632.
48. Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. *Arch Dermatol*. 2006;142(9):1138-1143.
49. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. *J Am Acad Dermatol*. 2004;51(5): 731-738.
50. Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg^{-1} ointment and tacrolimus 0.3 mg g⁻¹ ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. *Br J Dermatol*. 2007;157(5): 1005-1012.
51. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. *J Am Acad Dermatol*. 2004;51(5):723-730.
52. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid

- gel for plaque psoriasis treatment. *Arch Dermatol*. 2005; 141(1):43-46.
53. Elidel (pimecrolimus) Cream, 1% [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021302s018lbl.pdf. Accessed September 19, 2019.
 54. Protopic® (tacrolimus) [package insert]. Deerfield, IL: Astellas Pharma US, Inc.; 2011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf. Accessed September 19, 2019.
 55. Abedz N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. *Postepy Dermatol Alergol*. 2019;36(6):752-759.
 56. Fleischer AB Jr, Abramovits W, Breneman D, Jaracz E. US/Canada tacrolimus ointment study group. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. *J Dermatolog Treat*. 2007;18(3):151-157.
 57. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. *Arch Dermatol*. 2001;137(6):778-783.
 58. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association between malignancy and topical use of pimecrolimus. *JAMA Dermatol*. 2015;151(6):594-599.
 59. Segal AO, Ellis AK, Kim HL. CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. *Allergy Asthma Clin Immunol*. 2013;9(1):24.
 60. Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. *Psoriasis (Auckl)*. 2016;6:153-163.
 61. Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol*. 2009;60(1):120-124.
 62. Highton A, Quell J, Calcipotriene Study Group. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. *J Am Acad Dermatol*. 1995;32(1):67-72.
 63. Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. *J Am Acad Dermatol*. 1992;27(6 Pt 1):983-988.
 64. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. *Br J Dermatol*. 1994; 130(4):483-487.
 65. Feldman SR, Matheson R, Bruce S, et al. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. *Am J Clin Dermatol*. 2012;13(4):261-271.
 66. Ma L, Yang Q, Yang H, et al. Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. *Int J Dermatol*. 2016;55(1):106-113.
 67. Tying S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. *Int J Dermatol*. 2010;49(11):1328-1333.
 68. Feldman SR, Mills M, Brundage T, Eastman WJ. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. *J Drugs Dermatol*. 2013; 12(3):300-306.
 69. Choi JW, Choi JW, Kwon IH, Youn JI. High-concentration (20 $\mu\text{g g}^{-1}$) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial. *Br J Dermatol*. 2010;162(6): 1359-1364.
 70. Singh P, Gupta S, Abidi A, Krishna A. Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis. *J Drugs Dermatol*. 2013;12(8):868-873.
 71. Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. *Am J Clin Dermatol*. 2010;11(4):275-283.
 72. Ortonne JP, Noerrelund KL, Papp K, et al. Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. *Eur J Dermatol*. 2010;20(5):585-589.
 73. Queille-Roussel C, Hoffmann V, Ganslandt C, Hansen KK. Comparison of the antipsoriatic effect and tolerability of calcipotriol-containing products in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. *Clin Drug Investig*. 2012;32(9):613-619.
 74. van der Velden HM, Pasch MC, van Erp PE, et al. Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study. *J Dermatolog Treat*. 2010;21(1):13-22.
 75. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. *Eur J Dermatol*. 2010;20(4): 465-471.
 76. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. *J Am Acad Dermatol*. 2008;59(3):455-463.
 77. Devaux S, Castela A, Archier E, et al. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. *J Eur Acad Dermatol Venereol*. 2012;26(Suppl 3):52-60.
 78. Okubo Y, Natsume S, Usui K, Muro M, Tsuboi R. Combination therapy using maxacalcitol and corticosteroid lotions preliminary to monotherapy with maxacalcitol lotion for scalp psoriasis. *J Dermatolog Treat*. 2014;25(1):34-37.
 79. Langley RG, Gupta A, Papp K, Wexler D, Osterdal ML, Curcic D. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. *Dermatology*. 2011;222(2):148-156.
 80. Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris—a randomized phase III study (PSO-FAST). *J Drugs Dermatol*. 2015;14(12): 1468-1477.
 81. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the

- treatment of psoriasis vulgaris. *Br J Dermatol*. 2006;154(6):1155-1160.
82. Silver S, Tuppal R, Gupta AK, et al. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial. *J Drugs Dermatol*. 2013;12(8):882-887.
 83. Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. *J Drugs Dermatol*. 2013;12(1):92-98.
 84. Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. *J Dtsch Dermatol Ges*. 2014;12(8):667-682.
 85. Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. *Cochrane Database Syst Rev*. 2013;(3):CD005028.
 86. Menter A, Sofen H, Smith S, et al. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. *Cutis*. 2011;88(1):46-51.
 87. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. *Am J Clin Dermatol*. 2001;2(2):95-120.
 88. Kim GK. The rationale behind topical vitamin D analogs in the treatment of psoriasis: where does topical calcitriol fit in? *J Clin Aesthet Dermatol*. 2010;3(8):46-53.
 89. Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B. Interactions between calcipotriene and ultraviolet light. *J Am Acad Dermatol*. 1997;37(1):93-95.
 90. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. *J Am Acad Dermatol*. 2019;81(3):775-804.
 91. Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. *Psoriasis (Auckl)*. 2017;7:51-63.
 92. Yanaba K, Umezawa Y, Honda H, et al. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis. *J Dermatol*. 2016;43(4):443-444.
 93. Muro M, Kawakami H, Matsumoto Y, Abe N, Tsuboi R, Okubo Y. Topical combination therapy with vitamin D₃ and corticosteroid ointment for palmoplantar pustulosis: a prospective, randomized, left-right comparison study. *J Dermatolog Treat*. 2016;27(1):51-53.
 94. Tirado-Sanchez A, Ponce-Olivera RM. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. *Cutis*. 2012;90(3):140-144.
 95. Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. *J Am Acad Dermatol*. 2010;63(5):775-781.
 96. Mason A, Mason J, Cork M, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. *J Am Acad Dermatol*. 2013;69(5):799-807.
 97. Saraceno R, Camplone G, D'Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol(R) gel) in the treatment of scalp psoriasis: results from a study in 885 patients. *J Dermatolog Treat*. 2014;25(1):30-33.
 98. Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. *J Drugs Dermatol*. 2009;8(1):52-57.
 99. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—a randomized phase II study. *J Dermatolog Treat*. 2016;27(2):120-127.
 100. Sticherling M, Eicke C, Anger T. Practicability of combined treatment with calcipotriol/betamethasone gel (Daivobet(R) Gel) and improvement of quality of life in patients with psoriasis. *J Dtsch Dermatol Ges*. 2013;11(5):420-427.
 101. van de Kerkhof P, de Peuter R, Rytto J, Jansen JP. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. *Curr Med Res Opin*. 2011;27(1):225-238.
 102. Weinstein GD. Tazarotene gel: efficacy and safety in plaque psoriasis. *J Am Acad Dermatol*. 1997;37(2 Pt 3):S33-S38.
 103. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. *J Am Acad Dermatol*. 1998;38(5 Pt 1):705-711.
 104. Kumar U, Kaur I, Dogra S, De D, Kumar B. Topical tazarotene vs. coal tar in stable plaque psoriasis. *Clin Exp Dermatol*. 2010;35(5):482-486.
 105. Kaur I, Dogra S, Jain R, Kumar B. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. *Indian J Dermatol Venereol Leprol*. 2008;74(5):471-474.
 106. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. *J Am Acad Dermatol*. 2003;48(5):760-767.
 107. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. *Int J Dermatol*. 2001;40(1):64-66.
 108. Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. *J Am Acad Dermatol*. 2000;43(5 Pt 1):821-828.
 109. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. *Acta Derm Venereol*. 2007;87(2):167-168.
 110. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. *Cutis*. 2001;68(5):355-358.
 111. Tazorac® (tazarotene) cream, 0.05% and 0.1%, for topical use [packet insert]. Irvine, CA: Allergan; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021184s009lbl.pdf. Accessed October 21, 2019.
 112. Avage® (tazarotene) cream, 0.1% [package insert]. Irvine, CA: Allergan; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021184s009lbl.pdf. Accessed September 19, 2019.

113. Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-severe plaque psoriasis: a pooled analysis of two phase 3 studies. *J Drugs Dermatol*. 2018;17(8):855-861.
114. Sugarman JL, Gold LS, Lebwohl MG, Pariser DM, Alexander BJ, Pillai R. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. *J Drugs Dermatol*. 2017;16(3):197-204.
115. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. *Int J Dermatol*. 2001;40(3):210-212.
116. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. *J Am Acad Dermatol*. 1998;39(4 Pt 1):590-596.
117. Huang YC, Chou CL, Chiang YY. Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, inpatient left-to-right controlled study. *Lasers Surg Med*. 2013;45(2):102-107.
118. Koo K, Jeon C, Bhutani T. Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis. *J Dermatolog Treat*. 2017;28(8):702-708.
119. Cassano N, Mantegazza R, Battaglini S, Apruzzi D, Loconsole F, Vena GA. Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot randomized open-label study. *G Ital Dermatol Venereol*. 2010;145(6):789-792.
120. Seite S, Khemis A, Rougier A, Ortonne JP. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis. *Exp Dermatol*. 2009;18(12):1076-1078.
121. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. *Int J Dermatol*. 1999;38(1):16-24.
122. Akamine KL, Gustafson CJ, Yentzer BA, et al. A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis. *J Drugs Dermatol*. 2013;12(8):855-859.
123. Kircik L. Salicylic Acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. *J Drugs Dermatol*. 2011;10(3):270-273.
124. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. *Clin Ther*. 1998;20(2):283-291.
125. Kristensen B, Kristensen O. Topical salicylic acid interferes with UVB therapy for psoriasis. *Acta Derm Venereol*. 1991;71(1):37-40.
126. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad Dermatol*. 2009;60(4):643-659.
127. Tiplica GS, Salavastru CM. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. *J Eur Acad Dermatol Venereol*. 2009;23(8):905-912.
128. McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. *FASEB J*. 2005;19(8):1012-1014.
129. Jekler J, Swanbeck G. One-minute dithranol therapy in psoriasis: a placebo-controlled paired comparative study. *Acta Derm Venereol*. 1992;72(6):449-450.
130. Grattan C, Hallam F, Whitefield M. A new aqueous dithranol gel for psoriasis: comparison with placebo and calcipotriol ointment. *J Dermatolog Treat*. 1997;8(1):11-15.
131. de Korte J, van der Valk PG, Sprangers MA, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. *Br J Dermatol*. 2008;158(2):375-381.
132. Rogalski C, Grunewald S, Schetschorke M, et al. Treatment of plaque-type psoriasis with the 308 nm excimer laser in combination with dithranol or calcipotriol. *Int J Hyperthermia*. 2012;28(2):184-190.
133. Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. *J Dermatolog Treat*. 2004;15(1):14-22.
134. Slutsky JB, Clark RA, Remedios AA, Klein PA. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. *J Drugs Dermatol*. 2010;9(10):1258-1264.
135. Kanzler MH, Gorsulowsky DC. Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. *Br J Dermatol*. 1993;129(3):310-314.
136. Brouda I, Edison B, Van Cott A, Green BA. Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. *Cutis*. 2010;85(4):214-220.
137. Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. *J Drugs Dermatol*. 2009;8(4):351-357.
138. Abdallah MA, El-Khateeb EA, Abdel-Rahman SH. The influence of psoriatic plaques pretreatment with crude coal tar vs. petrolatum on the efficacy of narrow-band ultraviolet B: a half-vs.-half intra-individual double-blinded comparative study. *Photodermatol Photoimmunol Photomed*. 2011;27(5):226-230.
139. Roelofzen JH, Aben KK, Oldenhof UT, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. *J Invest Dermatol*. 2010;130(4):953-961.
140. Roelofzen JHJ, Aben KKH, Van de Kerkhof PCM, Van der Valk PGM, Kiemeneij L. Dermatological exposure to coal tar and bladder cancer risk: a case-control study. *Urol Oncol*. 2015;33(1):20.e19-20.e22.
141. Franssen ME, van der Wilt GJ, de Jong PC, Bos RP, Arnold WP. A retrospective study of the teratogenicity of dermatological coal tar products. *Acta Derm Venereol*. 1999;79(5):390-391.
142. Zangar RC, Springer DL, Buschbom RL, Mahlum DD. Comparison of fetotoxic effects of a dermally applied complex organic mixture in rats and mice. *Fundam Appl Toxicol*. 1989;13(4):662-669.
143. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. *J Am Acad Dermatol*. 2014;70(3):401.e1-401.e10. quiz 415.
144. Chern E, Yau D, Ho JC, et al. Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis. *Acta Derm Venereol*. 2011;91(4):447-451.
145. de Miguel R, el-Azhary R. Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the

- treatment of moderate to severe psoriasis. *Int J Dermatol*. 2009;48(6):653-658.
146. Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. *J Am Acad Dermatol*. 2013; 69(3):385-392.
 147. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. *Br J Dermatol*. 2010;163(2):402-411.
 148. de Jong EM, Mork NJ, Seijger MM, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. *Br J Dermatol*. 2003;148(2):318-325.
 149. Vena GA, Galluccio A, Pezza M, Vestita M, Cassano N. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study. *J Dermatolog Treat*. 2012;23(4): 255-260.
 150. Deng S, May BH, Zhang AL, Lu C, Xue CC. Topical herbal medicine combined with pharmacotherapy for psoriasis: a systematic review and meta-analysis. *Arch Dermatol Res*. 2013;305(3):179-189.
 151. Lin YK, See LC, Huang YH, et al. Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: a randomized, observer-blind, vehicle-controlled trial. *Phyto-medicine*. 2014;21(7):1015-1020.
 152. Jerner B, Skogh M, Vahlquist A. A controlled trial of acupuncture in psoriasis: no convincing effect. *Acta Derm Venereol*. 1997;77(2):154-156.
 153. Lu CJ, Xiang Y, Xie XL, Xuan ML, He ZH. A randomized controlled single-blind clinical trial on 84 outpatients with psoriasis vulgaris by auricular therapy combined with optimized Yinxieling Formula. *Chin J Integr Med*. 2012;18(3):186-191.
 154. Shan C, Yuan L, Xiuzhen B, Aiju Q. Treatment of psoriasis vulgaris by oral administration of yin xie ping granules—a clinical report of 60 cases. *J Tradit Chin Med*. 2006;26(3):198-201.
 155. Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C. Add-on effect of Chinese herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review. *Evid Based Complement Alternat Med*. 2013;2013:673078.
 156. Mose KF, Bygum A. Chinese herbal remedy found to contain steroids and antifungals. *Lancet*. 2019;393(10170):446.
 157. Wood B, Wishart J. Potent topical steroid in a Chinese herbal cream. *N Z Med J*. 1997;110(1055):420-421.
 158. Huang CW, Hwang IH, Lee YS, et al. Utilization patterns of traditional medicine in Taiwan and South Korea by using national health insurance data in 2011. *PLoS One*. 2018; 13(12):e0208569.
 159. Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with *Aloe vera* extract in a hydrophilic cream: a placebo-controlled, double-blind study. *Trop Med Int Health*. 1996;1(4):505-509.
 160. Paulsen E, Korsholm L, Brandrup F. A double-blind, placebo-controlled study of a commercial *Aloe vera* gel in the treatment of slight to moderate psoriasis vulgaris. *J Eur Acad Dermatol Venereol*. 2005;19(3):326-331.
 161. Guo X, Mei N. *Aloe vera*: a review of toxicity and adverse clinical effects. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev*. 2016;34(2):77-96.
 162. Ferreira M, Teixeira M, Silva E, Selores M. Allergic contact dermatitis to *Aloe vera*. *Contact Dermatitis*. 2007;57(4):278-279.
 163. Najafizadeh P, Hashemian F, Mansouri P, Farshi S, Surmaghi MS, Chalangari R. The evaluation of the clinical effect of topical St Johns wort (*Hypericum perforatum L.*) in plaque type psoriasis vulgaris: a pilot study. *Australas J Dermatol*. 2012;53(2):131-135.
 164. Mayser P, Mrowietz U, Arenberger P, et al. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. *J Am Acad Dermatol*. 1998;38(4): 539-547.
 165. Maruani A, Samimi M, Stembridge N, et al. Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. *Cochrane Database Syst Rev*. 2019;4:CD011541.
 166. Bittiner SB, Tucker WF, Cartwright I, Bleehe SS. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. *Lancet*. 1988;1(8582):378-380.
 167. Bjorneboe A, Smith AK, Bjorneboe GE, Thune PO, Drevon CA. Effect of dietary supplementation with n-3 fatty acids on clinical manifestations of psoriasis. *Br J Dermatol*. 1988;118(1): 77-83.
 168. Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. A systematic review of treatments for guttate psoriasis. *Br J Dermatol*. 2001;145(6):891-894.
 169. Grimminger F, Mayser P, Papavassilis C, et al. A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile. *Clin Investig*. 1993;71(8):634-643.
 170. Collier PM, Ursell A, Zaremba K, Payne CM, Staughton RC, Sanders T. Effect of regular consumption of oily fish compared with white fish on chronic plaque psoriasis. *Eur J Clin Nutr*. 1993;47(4):251-254.
 171. Gupta AK, Ellis CN, Goldfarb MT, Hamilton TA, Voorhees JJ. The role of fish oil in psoriasis. A randomized, double-blind, placebo-controlled study to evaluate the effect of fish oil and topical corticosteroid therapy in psoriasis. *Int J Dermatol*. 1990;29(8):591-595.
 172. Gupta AK, Ellis CN, Tellner DC, Anderson TF, Voorhees JJ. Double-blind, placebo-controlled study to evaluate the efficacy of fish oil and low-dose UVB in the treatment of psoriasis. *Br J Dermatol*. 1989;120(6):801-807.
 173. Danno K, Sugie N. Combination therapy with low-dose etretinate and eicosapentaenoic acid for psoriasis vulgaris. *J Dermatol*. 1998;25(11):703-705.
 174. Fernandes AR, Rose M, White S, Mortimer DN, Gem M. Dioxins and polychlorinated biphenyls (PCBs) in fish oil dietary supplements: occurrence and human exposure in the UK. *Food Addit Contam*. 2006;23(9):939-947.
 175. Ashley JT, Ward JS, Schafer MW, Stapleton HM, Velinsky DJ. Evaluating daily exposure to polychlorinated biphenyls and polybrominated diphenyl ethers in fish oil supplements. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess*. 2010;27(8):1177-1185.
 176. Rawn DF, Breakell K, Verigin V, Nicolidakis H, Sit D, Feeley M. Persistent organic pollutants in fish oil supplements on the Canadian market: polychlorinated biphenyls

- and organochlorine insecticides. *J Food Sci.* 2009;74(1):T14-T19.
177. Akintoye E, Sethi P, Harris WS, et al. Fish oil and perioperative bleeding. *Circ Cardiovasc Qual Outcomes.* 2018;11(11):e004584.
178. Begtrup KM, Krag AE, Hvas AM. No impact of fish oil supplements on bleeding risk: a systematic review. *Dan Med J.* 2017;64(5):A5366.
179. Morimoto S, Yoshikawa K. Psoriasis and vitamin D3. A review of our experience. *Arch Dermatol.* 1989;125(2):231-234.
180. Prystowsky JH, Knobler EH, Muzio PJ. Oral calcitriol (1,25-dihydroxyvitamin D3) does not augment UVB phototherapy for plaque psoriasis. *J Am Acad Dermatol.* 1996;35(2 Pt 1):272-274.
181. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. *Br J Dermatol.* 1996;134(6):1070-1078.
182. Siddiqui MA, Al-Khawajah MM. Vitamin D3 and psoriasis: a randomized double-blind placebo-controlled study. *J Dermatolog Treat.* 1990;1(5):243-245.
183. Merola JF, Han J, Li T, Qureshi AA. No association between vitamin D intake and incident psoriasis among US women. *Arch Dermatol Res.* 2014;306(3):305-307.
184. Vaughn AR, Branum A, Sivamani RK. Effects of turmeric (*Curcuma longa*) on skin health: a systematic review of the clinical evidence. *Phytother Res.* 2016;30(8):1243-1264.
185. Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. *Foods.* 2017;6(10):92.
186. Burrows NP, Turnbull AJ, Punchard NA, Thompson RP, Jones RR. A trial of oral zinc supplementation in psoriasis. *Cutis.* 1994;54(2):117-118.
187. National Institutes of Health. Office of Dietary Supplements. Zinc: Fact Sheet for Professionals. Available at: <https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/>. Accessed November 4, 2019.
188. Kia KF, Nair RP, Ike RW, Hiremagalore R, Elder JT, Ellis CN. Prevalence of anti gliadin antibodies in patients with psoriasis is not elevated compared with controls. *Am J Clin Dermatol.* 2007;8(5):301-305.
189. Ludvigsson JF, Lindelof B, Zingone F, Ciacci C. Psoriasis in a nationwide cohort study of patients with celiac disease. *J Invest Dermatol.* 2011;131(10):2010-2016.
190. Ojetti V, Aguilar Sanchez J, Guerriero C, et al. High prevalence of celiac disease in psoriasis. *Am J Gastroenterol.* 2003;98(11):2574-2575.
191. De Bastiani R, Gabrielli M, Lora L, et al. Association between coeliac disease and psoriasis: Italian primary care multicentre study. *Dermatology.* 2015;230(2):156-160.
192. Bhatia BK, Millsop JW, Debbaneh M, Koo J, Linos E, Liao W. Diet and psoriasis, part II: celiac disease and role of a gluten-free diet. *J Am Acad Dermatol.* 2014;71(2):350-358.
193. Michaelsson G, Gerden B, Hagforsen E, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. *Br J Dermatol.* 2000;142(1):44-51.
194. Tausk F, Whitmore SE. A pilot study of hypnosis in the treatment of patients with psoriasis. *Psychother Psychosom.* 1999;68(4):221-225.
195. Gaston L, Crombez JC, Lassonde M, Bernier-Buzzanga J, Hodgins S. Psychological stress and psoriasis: experimental and prospective correlational studies. *Acta Derm Venereol Suppl (Stockh).* 1991;156:37-43.
196. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). *Psychosom Med.* 1998;60(5):625-632.
197. Keinan G, Segal A, Gal U, Brenner S. Stress management for psoriasis patients: the effectiveness of biofeedback and relaxation techniques. *Stress Med.* 1995;11(1):235-241.
198. Zachariae R, Oster H, Bjerring P, Kragballe K. Effects of psychologic intervention on psoriasis: a preliminary report. *J Am Acad Dermatol.* 1996;34(6):1008-1015.
199. Coyle M, Deng J, Zhang AL, et al. Acupuncture therapies for psoriasis vulgaris: a systematic review of randomized controlled trials. *Forsch Komplementmed.* 2015;22(2):102-109.
200. Deng S, May BH, Zhang AL, Lu C, Xue CC. Plant extracts for the topical management of psoriasis: a systematic review and meta-analysis. *Br J Dermatol.* 2013;169(4):769-782.
201. Song P, Lysvand H, Yuhe Y, Liu W, Iversen OJ. Expression of the psoriasis-associated antigen, Pso p27, is inhibited by traditional Chinese medicine. *J Ethnopharmacol.* 2010;127(1):171-174.
202. Yao DN, Lu CJ, Wen ZH, et al. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial. *Trials.* 2016;17(1):140.
203. Henneicke-von Zepelin HH, Mrowietz U, Farber L, et al. Highly purified omega-3-polyunsaturated fatty acids for topical treatment of psoriasis. Results of a double-blind, placebo-controlled multicentre study. *Br J Dermatol.* 1993;129(6):713-717.
204. Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. *N Engl J Med.* 1993;328(25):1812-1816.
205. Perez A, Chen TC, Turner A, et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D³) for the treatment of psoriasis. *Br J Dermatol.* 1996;134(2):238-246.
206. Prystowsky JH, Muzio PJ, Sevran S, Clemens TL. Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D₃) on vitamin D photosynthesis in patients with psoriasis. *J Am Acad Dermatol.* 1996;35(5 Pt 1):690-695.
207. Antiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M. Oral curcumin (Meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris. *Biomed Res Int.* 2015;2015:283634.
208. Carrion-Gutierrez M, Ramirez-Bosca A, Navarro-Lopez V, et al. Effects of *Curcuma* extract and visible light on adults with plaque psoriasis. *Eur J Dermatol.* 2015;25(3):240-246.
209. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. *J Am Acad Dermatol.* 2008;58(4):625-631.
210. Michaelsson G, Kristjansson G, Pihl Lundin I, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. *Br J Dermatol.* 2007;156(4):659-666.
211. Addolorato G, Parente A, de Lorenzi G, et al. Rapid regression of psoriasis in a coeliac patient after gluten-free diet. A case report and review of the literature. *Digestion.* 2003;68(1):9-12.
212. Michaelsson G, Gerden B, Ottosson M, et al. Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. *Br J Dermatol.* 1993;129(6):667-673.
213. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. *J Am Acad Dermatol.* 2017;76(2):290-298.
214. Bozek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis Area and Severity Index, body surface area

- and Physician Global Assessment. *Adv Clin Exp Med*. 2017; 26(5):851-856.
215. Dauden E, Puig L, Ferrandiz C, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. *J Eur Acad Dermatol Venereol*. 2016; 30(Suppl 2):1-18.
 216. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res*. 2011;303(1):1-10.
 217. Dommasch ED, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. *Br J Dermatol*. 2010;162(4):835-842.
 218. American Academy of Dermatology. Measure 410 (Psoriasis: Clinical Response to Systemic Medications). Available at: <https://www.aad.org/member/practice/mips/measures/410a>. Accessed November 21, 2019.
 219. Kreft S, Kreft M, Resman A, Marko P, Kreft KZ. Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial—comparison to physician's estimations. *J Dermatol Sci*. 2006;44(1):21-27.
 220. Yune YM, Park SY, Oh HS, et al. Objective assessment of involved surface area in patients with psoriasis. *Skin Res Technol*. 2003;9(4):339-342.
 221. Savolainen L, Kontinen J, Alatalo E, Roning J, Oikarinen A. Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. *Acta Derm Venereol*. 1998;78(6):466-467.
 222. Savolainen L, Kontinen J, Roning J, Oikarinen A. Application of machine vision to assess involved surface in patients with psoriasis. *Br J Dermatol*. 1997;137(3):395-400.
 223. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. *Br J Dermatol*. 1991;124(6):565-570.
 224. Charman CR, Venn AJ, Williams HC. Measurement of body surface area involvement in atopic eczema: an impossible task? *Br J Dermatol*. 1999;140(1):109-111.
 225. Kragballe K, Gniadecki R, Mork NJ, Rantanen T, Stahle M. Implementing best practice in psoriasis: a Nordic expert group consensus. *Acta Derm Venereol*. 2014;94(5): 547-552.
 226. Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. *J Eur Acad Dermatol Venereol*. 2010;24(Suppl 2):2-9.
 227. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol*. 2009;23(Suppl 2):1-70.
 228. Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. *Australas J Dermatol*. 2013;54(2):148-154.
 229. Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. *Ann Rheum Dis*. 2014;73(1):238-242.
 230. Cabrera S, Chinniah N, Lock N, Cains GD, Woods J. Inter-observer reliability of the PASI in a clinical setting. *Australas J Dermatol*. 2015;56(2):100-102.
 231. Berth-Jones J, Thompson J, Papp K, Copenhagen Psoriasis Working Group. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. *Br J Dermatol*. 2008; 159(2):407-412.
 232. Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. *Br J Dermatol*. 2006;155(4): 707-713.
 233. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. *J Am Acad Dermatol*. 2004;51(4):563-569.
 234. Chularojanamontri L, Griffiths CEM, Chalmers RJG. Responsiveness to change and interpretability of the simplified psoriasis index. *J Invest Dermatol*. 2014;134(2): 351-358.
 235. Chaptini C, Quinn S, Marshman G. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study. *Australas J Dermatol*. 2016;57(3):e72-e75.
 236. Chow C, Simpson MJ, Luger TA, Chubb H, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment. *J Eur Acad Dermatol Venereol*. 2015;29(7):1406-1414.
 237. Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). *J Eur Acad Dermatol Venereol*. 2015;29(3):452-456.
 238. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. *J Drugs Dermatol*. 2003;2(3):260-266.
 239. Gulliver W, Lynde C, Dutz JP, et al. Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis. *J Cutan Med Surg*. 2015;19(1):22-27.
 240. Cappelleri JC, Bushmakina AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. *Qual Life Res*. 2013;22(9):2489-2499.
 241. Gottlieb AB, Merola JF, Chen R, Levi E, Duffin KC. Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA x BSA) composite tool: an analysis of apremilast phase 3 ESTEEM data. *J Am Acad Dermatol*. 2017; 77(6):1178-1180.
 242. Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2. *J Drugs Dermatol*. 2017;16(2):147-153.
 243. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. *J Am Acad Dermatol*. 2013;69(6):931-937.
 244. Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. *J Dermatolog Treat*. 2013;24(5):356-360.
 245. Revicki DA, Jin Y, Wilson HD, Chau D, Viswanathan HN. Reliability and validity of the psoriasis symptom inventory in

- patients with moderate-to-severe psoriasis. *J Dermatolog Treat.* 2014;25(1):8-14.
246. Viswanathan HN, Mutebi A, Milmont CE, et al. Measurement properties of the psoriasis symptom inventory electronic daily diary in patients with moderate to severe plaque psoriasis. *Value Health.* 2017;20(8):1174-1179.
247. Martin ML, McCarrier KP, Chiou CF, et al. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. *J Dermatolog Treat.* 2013; 24(4):255-260.
248. Strober B, van de Kerkhof PCM, Callis Duffin K, et al. Feasibility and utility of the Psoriasis Symptom Inventory (PSI) in clinical care settings: a study from the International Psoriasis Council. *Am J Clin Dermatol.* 2019;20(5):699-709.
249. Shikhar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. *Health Qual Life Outcomes.* 2003;1:53.
250. Shikhar R, William MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. *Health Qual Life Outcomes.* 2006;4:71.
251. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. *Clin Exp Dermatol.* 1994;19(3):210-216.
252. Mazzotti E, Picardi A, Sampogna F, et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. *Br J Dermatol.* 2003;149(2):318-322.
253. Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: data from Danish inpatients and outpatients. *Acta Derm Venereol.* 2000;80(4):272-276.
254. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the 'Eppendorf Itch Questionnaire'. *Int Arch Allergy Immunol.* 2001;124(1-3):326-331.
255. Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. *J Am Acad Dermatol.* 2008;59(2):234-244.
256. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. *Br J Dermatol.* 2010;162(3):587-593.
257. Gottlieb A, Feng J, Harrison DJ, Globe D. Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. *J Am Acad Dermatol.* 2010;63(4):580-586.
258. Haydek CG, Love E, Mollanazar NK, et al. Validation and banding of the ItchyQuant: a self-report itch severity scale. *J Invest Dermatol.* 2017;137(1):57-61.
259. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. *Br J Dermatol.* 2006;154(4):719-725.
260. Kimball AB, Naegeli AN, Edson-Heredia E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. *Br J Dermatol.* 2016; 175(1):157-162.
261. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. *J Am Acad Dermatol.* 2014;70(5):871-881. e871-830.
262. Mamolo CM, Bushmakina AG, Cappelleri JC. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. *J Dermatolog Treat.* 2015;26(2):121-123.
263. Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. *Int J Dermatol.* 2015;54(6):715-722.
264. Pedersen CB, McHorney CA, Larsen LS, Lophaven KW, Moeller AH, Reaney M. Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris. *J Dermatolog Treat.* 2017;28(3):213-220.
265. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. *Acta Derm Venereol.* 2012;92(5):502-507.
266. Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. *Acta Derm Venereol.* 2012;92(5):497-501.
267. Love EM, Marrazzo GA, Kini S, Veledar E, Chen SC. ItchyQoL bands: pilot clinical interpretation of scores. *Acta Derm Venereol.* 2015;95(1):114-115.
268. Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. *Br J Dermatol.* 2007;156(4):667-673.
269. Mattered U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. *Acta Derm Venereol.* 2011;91(6):674-679.
270. Al-Qarqaz FA, Aboosi M, Al-Shiyab D, Bataineh A. Using pruritus grading system for measurement of pruritus in patients with diseases associated with itch. *J Med J.* 2012; 46(1):39-44.
271. Li L, Liu X, Herr K. Postoperative pain intensity assessment: a comparison of four scales in Chinese adults. *Pain Med.* 2007; 8(3):223-234.
272. Flytstrom I, Stenberg B, Svensson A, Bergbrant IM. Patients' visual analogue scale: a useful method for assessing psoriasis severity. *Acta Derm Venereol.* 2012;92(4):347-348.
273. Erickson S, Kim BS. Research techniques made simple: itch measurement in clinical trials. *J Invest Dermatol.* 2019;139(2): 264-269 e261.
274. Administrative Regulation-Evidence-Based Clinical Practice Guidelines. In: *American Academy of Dermatology.* 2014.

Workgroup members disclosures

April W. Armstrong,* MD, MPH, served as an investigator for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Dermavant Sciences, Dermira, Eli Lilly and Company, Janssen-Ortho Inc, LEO Pharma Inc, National Institutes of Health, Novartis, Regeneron, and UCB receiving grants and/or research funding; as an investigator for Regeneron and Sanofi receiving no compensation; as an advisory board member for AbbVie, Amgen, Janssen-Ortho Inc, Merck & Co, Inc, Novartis, Pfizer, Inc, and UCB receiving honoraria; as a consultant for AbbVie, Bristol-Myers Squibb, Celgene, Dermavant, Eli Lilly and Company, Genentech, Sanofi Genzyme, GlaxoSmithKline, Janssen-Ortho Inc, Janssen Pharmaceuticals, Inc, LEO Pharma Inc, Menlo Therapeutics, Modernizing Medicine, Novartis Pharmaceuticals Corp, Ortho Dermatologics, Pfizer, Inc, Regeneron, Science 37, Inc, and Valeant receiving honoraria; as a speaker for AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Regeneron Pharmaceuticals, Inc, and Sanofi receiving honoraria; and as a data safety member for AbbVie, Boehringer Ingelheim, Merck & Co, Inc, and Parexel receiving honoraria. Cody Connor, MD has no relationships to disclose.

Kelly M. Cordoro,* MD, served as a consultant for Valeant receiving honoraria; as a consultant for Pfizer, Inc receiving fees; as an advisory board member for Anacor Pharmaceuticals, Inc receiving honoraria; and in another position as a member of the Scientific Steering Committee for Celgene receiving fees.

Dawn M.R. Davis, MD, served as an investigator for Regeneron receiving no compensation.

Boni E. Elewski,* MD, served as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, LEO Pharma, Lilly ICOS LLC, Menlo Therapeutics, Novan (receiving no fees), Novartis Pharmaceuticals Corp, Pfizer, Inc, Sun Pharmaceutical Industries, Ltd, Valeant Pharmaceuticals International, and Verrica Pharmaceuticals receiving honoraria; as a principal investigator for AbbVie, Amgen, AnaptysBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Incyte Corporation, InflaRX GmbH, Janssen-Ortho Inc, LEO Pharma, Menlo Therapeutics, Merck & Co, Inc, Novartis Pharmaceuticals Corp, Pfizer, Inc, Regeneron, Sun Pharmaceuticals, Ltd, Valeant Pharmaceuticals International, Vanda Pharmaceuticals, and Vioment receiving grants/research funding; as an advisory board member for Foundation for Research & Education of Dermatology, LEO Pharma, and Verrica Pharmaceuticals receiving honoraria; and in another role for Hoffman-La Roche Ltd receiving fees.

Craig A. Elmets, MD, served as a consultant for Ferndale Laboratories, Inc receiving honoraria; as a

consultant/advisory board member for Vertex Pharmaceuticals receiving fees and/or honoraria; as a principal investigator for the California Association of Winegrape Growers receiving grants and/or research funding; as an investigator for Elorac, Inc, Idera Pharmaceuticals, Inc, Kyowa Hakko USA, and Solgenix LLC receiving grants/research funding; as a data safety monitoring board member for Astellas Pharma US, Inc, and LEO Laboratories Ltd receiving fees; as a stockholder for Medgenics, Inc receiving no fees; and as a stockholder for Aevi Genomic Medicine (receiving stock) and Immunogen (paid to spouse).

Joel M. Gelfand,* MD, MSCE, served as a consultant for AbbVie, BMS, Boehringer Ingelheim, Dermira, Dr. Reddy, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Menlo Therapeutics, Novartis Pharmaceuticals Corp, Pfizer, Inc, Regeneron, Sanofi US Services, Sun Pharmaceutical Industries Ltd, UCB (DSMB), and Valeant Pharmaceuticals North America LLC receiving honoraria; as a consultant for BMS receiving fees; as speaker and/or faculty education for CME supported by Eli Lilly receiving fees; as a principal investigator for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Novartis Pharmaceuticals Corp, Ortho Dermatologics, Pfizer, Inc, Regeneron, and Sanofi/Sanofi US Services receiving grants/research funding; as an investigator for Sanofi receiving grants and/or research funding; as an advisory board member for Sanofi US Services receiving honoraria; as a data safety monitoring board member for Coherus Biosciences and Merck & Co, Inc receiving honoraria; received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly, Ortho Dermatologics, and Novartis; in another role for Elsevier, Inc receiving no compensation; in another role for Eli Lilly, Neuroderm Ltd, and UCB receiving fees; in another role for Resiquimod receiving patent royalties or other compensation for intellectual rights; and in another role for Daavlin Company receiving equipment.

Kenneth B. Gordon,* MD, served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Dermira, Dermavant Sciences, Kyowa Hakko Kirin Pharma, Inc, LEO Pharma, Ortho Dermatologics, Sun Pharmaceuticals Ltd., and UCB receiving honoraria; as a consultant for Genzyme receiving fees; as a principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck & Co, Inc, and Novartis Pharmaceuticals Corp receiving grants and/or research funding; and as an advisory board member for Celgene Corporation, Janssen Pharmaceuticals Inc, Lilly ICOS LLC, Novartis Pharmaceuticals Corp, and Pfizer, Inc receiving honoraria.

Alice B. Gottlieb,* MD, PhD, served as a consultant for Abbott Laboratories, AbbVie, Akros Pharma, Inc, Allergan, Amgen, Amicus Therapeutics, Baxalta Incorporated, Bristol-Myers Squibb, Canfite, Celgene Corporation, CSL Behring, Dermira, Dr. Reddy, DUSA Pharmaceuticals, Inc, GlaxoSmithKline, Incyte Corporation, KPI Therapeutics, Lilly ICOS LLC, Meiji Seika Pharma Co, Ltd, Merck & Co, Inc, Mitsubishi Pharma, Novartis Pharmaceuticals Corp, Sanofi-Aventis, Sienna Biopharmaceuticals, Sun Pharmaceutical Industries, Takeda Pharmaceuticals USA, Inc, Teva, UCB, Valeant Pharmaceuticals International, Valeant Pharmaceuticals North America LLC, XBiotech, and Xenoport, Inc receiving honoraria; as a consultant for Aclaris Therapeutics, Inc, Avotres Inc, Merck & Co Inc, and XBiotech receiving no compensation; as a consultant for XBiotech receiving stock options; as a speaker for AbbVie, Eli Lilly, and Janssen Biotech receiving honoraria; as a principal investigator/investigator for Abbott Laboratories, AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene Corporation, Coronado Biosciences, Immune Control, Incyte Corporation, Janssen Biotech, Janssen-Ortho, Inc, LEO Pharma, Lerner Medical Devices, Inc, Lilly ICOS LLC, Merck & Co, Inc, Novartis Pharmaceuticals Corp, Novo Nordisk A/S, Pfizer Inc, UCB, Xbiotech, and Xenoport, Inc receiving grants/research funding; as a principal investigator for Janssen-Ortho, Inc receiving honoraria; as an advisory board member for Abbott Laboratories, Actelion, Allergan, Amgen, Astellas Pharma US, Inc, Beiersdorf, Inc, BMS, Celgene Corporation, Coronado Biosciences, Dermira, Dr. Reddy, Genentech, Janssen-Ortho, Inc, Janssen Biotech, LEO Pharma US, Lilly ICOS LLC, Novartis Pharmaceuticals Corp, Novo Nordisk A/S, Pfizer, Inc, UCB, and Valeant receiving honoraria; in another role for Amgen receiving grants and/or research funding; in another role for Crescendo Bioscience and Karyopharm Therapeutics receiving no compensation; in another role (Data Safety) for Catabasis Pharmaceuticals, Inc receiving honoraria; in another role for DermiPsor receiving honoraria; and in another role for XBiotech receiving stock options.

Daniel H. Kaplan, MD, PhD, served as a consultant for Eli Lilly and Company, and Galderma Laboratories LP, receiving no compensation, and as a member of the data safety monitoring board for Hapten Sciences receiving fees.

Arthur Kavanaugh,* MD served as a principal investigator for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly and Company, Janssen Biotech, Novartis, Pfizer, Inc, and UCB receiving grants/research funding.

Matthew Kiselica, BA, BS, has no relationships to disclose.

Dario Kivelevitch, MD, has served as a speaker for Eli Lilly and Company receiving honoraria, and has a first-degree relative employed by Boehringer Ingelheim.

Neil J. Korman,* MD, PhD, served as a consultant for Novartis Pharmaceuticals Corp receiving honoraria; as a consultant for Dr. Reddy's Laboratory receiving fees; as a speaker for AbbVie, Celgene, Eli Lilly, Genentech, Janssen, Novartis, Regeneron, and Sanofi receiving honoraria; as a principal investigator for AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Chugai, Dermira, Eli Lilly and Company, Kyowa Hakko Kirin Pharma, Inc, LEO Pharma, Menlo Therapeutics, Merck, Pfizer, Principia Biopharma Inc, Prothena, Regeneron, Rhizen, Inc, Syntimmune, Trevi, UCB, and XBiotech receiving grants and/or research funding; as an advisory board member for Amgen, Celgene Corporation, Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Novartis Pharmaceuticals Corp, Pfizer, Inc, Principia Biopharma, and UCB receiving honoraria; as an advisory board member for Dr. Reddy's Laboratory, Immune Pharmaceuticals, Regeneron, Sanofi, Sun Pharma, and Valeant receiving fees; as an advisory board member/consultant for AbbVie, Eli Lilly, GlaxoSmithKline, Pfizer Inc, and Principia receiving honoraria/fees; and in another role for Janssen Pharmaceuticals, Inc receiving grants and/or research funding.

Daniela Kroshinsky, MD, MPH, has no relationships to disclose.

Mark Lebwohl,* MD, served as a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Inc, Avotres, BirchBioMed, BMD Skincare, Inc, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Inc, EMD Serono, Evelo Biosciences, Inc, Facilitation of International Dermatology Education, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma, Menlo Therapeutics, Mitsubishi Pharma, Neuroderm Ltd, Pfizer, Inc, Promius/Dr. Reddy, Theravance Biopharma, and Verrica Pharmaceuticals receiving honoraria; as a principal investigator or investigator for AbbVie, Amgen, Inc, Arcutis Inc, AstraZeneca, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Incyte Corporation, Janssen Research and Development LLC/Johnson & Johnson, LEO Pharma, Medimmune, Novartis Pharmaceuticals Corp, Ortho-Dermatologics, Pfizer, Inc, SCIDerm, UCB, and ViDac Pharma receiving grants and/or research funding; and in another role for Corrona, Inc, Facilitation of International Dermatology Education, and the Foundation for Research and Education in Dermatology receiving honoraria.

Craig L. Leonardi,* MD, served as a consultant/advisory board member for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, LEO Pharma A/S, Ortho Dermatologics, Pfizer, Inc, Sandoz (a Novartis Company), UCB, and Vitae receiving honoraria; as a speaker for AbbVie, Amgen, Celgene Corporation, Eli Lilly and Company, Novartis, Sun Pharmaceutical, Ltd, and UCB receiving honoraria; and as a principal investigator for Actavis, Amgen, AnaptysBio, Boehringer Ingelheim, Celgene Corporation, Cellceutix, Coherus Biosciences, Corrona, Dermira, Eli Lilly and Company, Galderma Laboratories, LP, Glenmark Generics, Inc, Janssen Pharmaceuticals, Inc, LEO Pharma Inc, Merck, Novartis, Novella, Pfizer, Inc, Sandoz (a Novartis Company), Sienna Biopharmaceuticals, Stiefel (a GSK company), UCB, and Warner Chilcott receiving other financial benefits (fee for service).

Jason Lichten, MD, has no relationships to disclose.

Henry W. Lim, MD, served as a principal or coinvestigator for Beiersdorf, Inc, Estée Lauder, Ferndale Laboratories, Inc, Incyte, and Unigen receiving grants and/or research funding; as an investigator for L'Oréal USA Inc receiving grants/research funding; as a consultant for ISDIN and Pierre Fabre Dermatologie receiving fees; as a speaker and/or faculty education for Eli Lilly and Company and Pierre Fabre Dermatologie receiving honoraria; as a speaker/faculty education for Pierre Fabre Dermatologie receiving grants/research funding; as a speaker/faculty education for Johnson and Johnson and RaMedical receiving fees; and as an advisory board member for Ferndale Laboratories and Galderma Laboratories, LP receiving honoraria.

Nehal N. Mehta,* MD, MSCE, is a full-time United States government employee and has served as a consultant for Amgen, Eli Lilly, and LEO Pharma receiving grants/other payments; as principal investigator and/or investigator for AbbVie, Celgene, Janssen Pharmaceuticals, Inc, and Novartis receiving grants and/or research funding; and as a principal investigator for the National Institutes of Health receiving grants and/or research funding.

Alan Menter,* MD, served as a consultant for Abbott Labs, AbbVie, Amgen, Eli Lilly and Company, Galderma USA, Janssen Pharmaceuticals Inc, LEO Pharma US, Menlo Therapeutics, Novartis, Sienna Biopharmaceuticals, and Wyeth Labs receiving honoraria; as a consultant for New Enterprise Associates, Promius Pharma LLC, Sienna Biopharmaceuticals, Spherix Global Insights US, UCB, and Valeant Pharmaceuticals North America receiving fees; as a consultant for Afecta Pharmaceuticals receiving no

compensation; as a speaker for Abbott Labs, AbbVie, Amgen, Janssen Biotech, LEO Pharma US, Pfizer, Inc, Promius Pharma LLC, Sienna Pharmaceuticals, UCB, and Wyeth Labs receiving honoraria; as a principal investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Medimetriks Pharmaceuticals, Inc, Merck & Co, Inc, Novartis Pharmaceutical Corp, and Pfizer, Inc, receiving grant and/or research funding; as an investigator for Eli Lilly and Company and UCB receiving honoraria; as an investigator for Abbott Labs, LEO Pharma US, and Sienna Biopharmaceuticals receiving grants; as an advisory board member for Abbott Labs, AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, LEO Pharma US, Medscape, Pfizer, Inc, and Sienna Biopharmaceuticals receiving honoraria; as an advisory board member for Amgen receiving grant and/or research funding; as an advisory board member for Afecta Pharmaceuticals receiving no compensation; and as an independent contractor for Prime Education receiving fees.

Amy S. Paller,* MD, served as a consultant for Amgen, Amicus Therapeutics, Anacor Pharmaceuticals, Inc, Aqua Pharmaceuticals, Boehringer Ingelheim International GmbH, BridgeBio Pharma, Castle Creek Pharma, Celgene Corporation, Chameleon Communications, Dermavant Sciences, Dermira, Eli Lilly and Company, Forte Biosciences, Galderma Laboratories, LP, LEO Pharma, Genentech, Menlo Therapeutics, MorphoSys AG, Novartis Pharmaceuticals Corp, Pfizer Inc, Pierre Fabre Dermatologie, Proctor and Gamble, Regeneron, Sanofi, Scioderm, Shire, Sol-Gel Technologies, Stiefel (a GSK company), Target Pharma, Theravance Biopharma, UCB, Union Therapeutic, Valeant Pharmaceuticals North America LLC, Vitae Pharmaceuticals, and Verrica Pharmaceuticals receiving honoraria; as a speaker/educator for Expanscience receiving honoraria; as a principal investigator for AbbVie, Amgen, Anacor Pharmaceuticals, Inc, AnaptysBio, Celgene Corporation, Eli Lilly, Galderma, Janssen Pharmaceuticals, Inc, LEO Pharma, Regeneron, and Scioderm, receiving no compensation; and as an advisory board member for Menlo Therapeutics receiving honoraria.

Sylvia L. Parra, MD, has no relationships to disclose.

Arun L. Pathy, MD, has no relationships to disclose.

Elizabeth A. Farley Prater, MD, has no relationships to disclose.

Reena N. Rupani, MD, served as speaker for Nutrafol receiving honoraria.

Michael Siegel, PhD, served as a consultant for Insmmed Inc, and Oricula Therapeutics, LLC receiving fees.

Benjamin Stoff, MD, MA, served as an investigator for Celtaxsys, Inc receiving fees.

Bruce E. Strober,* MD, PhD, served as a consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene Corporation, Dermira, Eli Lilly and Company, GlaxoSmithKline, Janssen-Ortho, Inc, LEO Pharma, Maruho Co, Ltd, Medac Pharma, Inc, Menlo Therapeutics, Novartis Pharmaceuticals Corp, Ortho Dermatologics, Pfizer, Inc, Sanofi-Regeneron, Sun Pharmaceuticals Industries, and UCB receiving honoraria; as a consultant for Affibody, Arena, Bristol-Myers Squibb, Dermavant, Meiji Seika Pharma Co, Ltd, Sebela Pharmaceuticals, Sirtris, and UCB receiving fees; as a principal investigator for AbbVie, Boehringer Ingelheim, Celgene Corporation, Eli Lilly and Company, Galderma, Janssen-Ortho, Inc, Merck & Co, Pfizer, Inc, Sienna, and Sun Pharmaceutical Industries receiving no compensation; as an investigator for Cara Therapeutics receiving no compensation; as an advisory board member for AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Dermira, Dr. Reddy's Laboratory, Eli Lilly and Company, Janssen-Ortho, Inc, Novartis Pharmaceuticals Corp, Pfizer, Inc, Sanofi-Regeneron, Sun Pharmaceuticals Industries, and UCB receiving honoraria; as consultant/advisory board for AstraZeneca Pharmaceuticals LP receiving fees/honoraria; and in another role for AbbVie and Janssen-Ortho, Inc receiving no compensation.

Emily B. Wong, MD, has no relationships to disclose.

Jashin J. Wu,* MD, served as a consultant for AbbVie, Allergan, Almirall, Amgen, Arcutis, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy's Laboratories, Eli Lilly and Company, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Inc, Promius Pharma, Regeneron, Sun Pharmaceutical Industries, Ltd, UCB, and Valeant Pharmaceuticals North America, LLC receiving fees and/or honoraria; as a speaker for AbbVie, Celgene, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical Industries Ltd, UCB, and Valeant Pharmaceuticals North America LLC receiving honoraria; and as a principal/investigator for AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Coherus Biosciences, Dermira, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Merck & Co, Inc, Novartis, Pfizer, Inc, Regeneron, Sandoz (a Novartis Company), and Sun Pharmaceutical Industries Ltd receiving research and/or grant funding.

Vidhya Hariharan, PhD has no relationships to disclose.

APPENDIX

Methods

A multidisciplinary workgroup (WG) of psoriasis experts consisting of dermatologists (including private practitioners), a rheumatologist, a cardiologist, and representatives from a patient advocacy organization, was convened to update and expand on the previously published 2008 American Academy of Dermatology (AAD) psoriasis guideline.¹²⁷ The WG determined the scope of the guideline and identified important clinical questions with regard to psoriasis treatment with topical agents and alternative medicine (AM) (Table 1). WG members completed a disclosure of interests that was periodically updated and reviewed for potentially relevant conflicts of interests throughout guideline development. If a relevant conflict was noted, a balance of conflicted and nonconflicted WG members was used to draft initial recommendations.

An evidence-based model was used, and evidence was obtained using a search of the PubMed and MEDLINE databases from January 1, 2008, to December 31, 2017, for clinical questions addressed in the previous version of this guideline published in 2008-2011, and for all newly identified clinical questions. Searches were limited to publications in the English language. Medical Subject Heading terms used in various combinations in the literature search included psoriasis (vulgaris, plaque, guttate, erythrodermic, pustular, palmoplantar, inverse, nail); topical corticosteroids, calcipotriol, calcineurin inhibitors (tacrolimus, pimecrolimus), combination, switch, failure (primary, secondary), alternate, cessation, emollients, salicylic acid, anthralin, body surface area (BSA), psoriasis area and severity index (PASI), physician global assessment (PGA), psoriasis symptom inventory (PSI), dermatology of life quality index (DLQI), pruritus assessment, traditional Chinese medicine, *Aloe vera*, St John's wort, fish oil, vitamin D, turmeric (curcumin), zinc, hypnosis, meditation, and stress reduction.

After removal of duplicate data, 287 (157 [topical], 66 [severity measures], 64 [AM]) articles were retained for final review based on relevancy and the highest level of available evidence for the outlined clinical questions. Evidence tables were generated for these studies and used by the WG in developing recommendations. The Academy's prior published guidelines on psoriasis were evaluated, as were other current published guidelines on psoriasis as part of the evidence review.

The available evidence was evaluated using a unified system called the Strength of Recommendation Taxonomy developed by editors of the US family medicine and primary care journals

(ie, *American Family Physician*, *Family Medicine*, *Journal of Family Practice*, and *BMJ USA*). Evidence was graded using a 3-point scale based on the quality of methodology (eg, randomized controlled trial, case-control, prospective/retrospective cohort, case series, etc) and the overall focus of the study (ie, diagnosis, treatment/prevention/screening, or prognosis) as follows:

- I. Good-quality patient-oriented evidence (ie, evidence measuring outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, and quality of life)
- II. Limited-quality patient-oriented evidence
- III. Other evidence, including consensus guidelines, opinion, case studies, or disease-oriented evidence (ie, evidence measuring intermediate, physiologic, or surrogate end points that may or may not reflect improvements in patient outcomes)

Clinical recommendations were developed on the best available evidence tabled in the guideline. These are ranked as follows:

- A. Recommendation based on consistent and good-quality patient-oriented evidence
- B. Recommendation based on inconsistent or limited-quality patient-oriented evidence
- C. Recommendation based on consensus, opinion, case studies, or disease-oriented evidence

In those situations where documented evidence-based data is not available, we have used expert opinion to generate our clinical recommendations or opted not to issue a recommendation.

This guideline has been developed in accordance with the AAD/AAO Association Administrative Regulations for Evidence-based Clinical Practice Guidelines (May 2014),²⁷⁴ which includes the opportunity for review and comment by the entire AAD membership and final review and comment by the AAD Board of Directors. Additionally, this guideline is developed in collaboration with the National Psoriasis Foundation (NPF) and as part of the review process; the NPF medical board members provided their feedback. This guideline will be considered current for a period of 5 years from the date of publication unless reaffirmed, updated, or retired before that time.

Definition

Psoriasis vulgaris is a chronic inflammatory skin disease that classically presents with well-demarcated, red plaques with silvery scale, commonly involving the scalp, elbows, knees, and presacral region, though any area of skin may be involved, including the palms, soles, nails, and genitalia. While the severity of psoriasis is defined in part by the total body surface area (BSA) involved, with less than 3% BSA considered mild, 3% to 10% BSA considered moderate, and greater than 10% considered severe disease, psoriasis can be severe irrespective of BSA, when it has serious emotional consequences or when it occurs in select locations, including, but not restricted to, the hands, feet, scalp, face, genital area, or when it causes intractable pruritus. The Psoriasis Area Severity Index (PASI) is a more specific means of quantifying the extent and severity of psoriasis, because it takes into account not only BSA but also the intensity of redness, scaling, and plaque thickness, ultimately producing a score from 0 (no disease) to 72 (maximal disease severity). The PASI is used for monitoring response to treatments in clinical trials and as a research tool to judge the severity of psoriasis. It is rarely used by dermatologists in clinical practice to guide management.

Psoriasis is an inflammatory, immune-mediated condition involving cutaneous T-cells, dendritic cells, and keratinocytes with subsequent release of a variety of cytokines and other soluble mediators. These chemical signals are responsible for keratinocyte hyperproliferation manifesting as characteristic scaly plaques, and they also contribute to the augmented inflammation underlying a number of systemic disease associations, including metabolic syndrome, cardiovascular disease, and psoriatic arthritis. To inhibit the inflammation underpinning this condition, a number of topical and systemic medications have been created with varying success. Topical treatments refer to agents that are applied directly on the skin in order to exert their therapeutic action. AM is a group of diverse medical and health care practices and products that are not presently considered to be part of conventional medicine. These therapies can be defined as alternative when are used in place of conventional treatments and complementary when used together with conventional treatments.